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Abstract
Improving the reproducibility of biomedical research is a major challenge. Transparent and
accurate reporting is vital to this process; it allows readers to assess the reliability of the
findings and repeat or build upon the work of other researchers. The ARRIVE guidelines
(Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors
and journals identify the minimum information necessary to report in publications describing
in vivo experiments. Despite widespread endorsement by the scientific community, the
impact of ARRIVE on the transparency of reporting in animal research publications has
been limited. We have revised the ARRIVE guidelines to update them and facilitate their use
in practice. The revised guidelines are published alongside this paper. This explanation and
elaboration document was developed as part of the revision. It provides further information
about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence
for their inclusion in the guidelines, elaboration of details to report, and examples of good
reporting from the published literature. This document also covers advice and best practice
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Introduction
Transparent and accurate reporting is essential to improve the reproducibility of scientific
research; it enables others to scrutinise the methodological rigour of the studies, assess how
reliable the findings are, and repeat or build upon the work.
However, evidence shows that the majority of publications fail to include key information
and there is significant scope to improve the reporting of studies involving animal research [1–
4]. To that end, the UK National Centre for the 3Rs (NC3Rs) published the ARRIVE (Animal
Research: Reporting In Vivo Experiments) guidelines in 2010. The guidelines are a checklist of
information to include in a manuscript to ensure that publications contain enough information
to add to the knowledge base [5]. The guidelines have received widespread endorsement from
the scientific community and are currently recommended by more than a thousand journals,
with further endorsement from research funders, universities, and learned societies worldwide.
Studies measuring the impact of ARRIVE on the quality of reporting have produced mixed
results [6–11], and there is evidence that in vivo scientists are not sufficiently aware of the
importance of reporting the information covered in the guidelines and fail to appreciate the
relevance to their work or their research field [12].
As a new international working group—the authors of this publication—we have revised the
guidelines to update them and facilitate their uptake; the ARRIVE guidelines 2.0 are published
alongside this paper [13]. We have updated the recommendations in line with current best prac-
tice, reorganised the information, and classified the items into two sets. The ARRIVE Essential
10 constitute the minimum reporting requirement, and the Recommended Set provides further
context to the study described. Although reporting both sets is best practice, an initial focus on
the most critical issues helps authors, journal staff, editors, and reviewers use the guidelines in
practice and allows a pragmatic implementation. Once the Essential 10 are consistently reported
in manuscripts, items from the Recommended Set can be added to journal requirements over
time until all 21 items are routinely reported in all manuscripts. Full methodology for the revi-
sion and the allocation of items into sets is described in the accompanying publication [13].
A key aspect of the revision was to develop this explanation and elaboration document to
provide background and rationale for each of the 21 items of ARRIVE 2.0. Here, we present
additional guidance for each item and subitem, explain the importance of reporting this infor-
mation in manuscripts that describe animal research, elaborate on what to report, and provide
supporting evidence. The guidelines apply to all areas of bioscience research involving living
animals. That includes mammalian species as well as model organisms such as Drosophila or
Caenorhabditis elegans. Each item is equally relevant to manuscripts centred around a single
animal study and broader-scope manuscripts describing in vivo observations along with other
types of experiments. The exact type of detail to report, however, might vary between species
and experimental setup; this is acknowledged in the guidance provided for each item.
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We recognise that the purpose of the research influences the design of the study. Hypothe-
sis-testing research evaluates specific hypotheses, using rigorous methods to reduce the risk of
bias and a statistical analysis plan that has been defined before the study starts. In contrast,
exploratory research often investigates many questions simultaneously without adhering to
strict standards of rigour; this flexibility is used to develop or test novel methods and generate
theories and hypotheses that can be formally tested later. Both study types make valuable contri-
butions to scientific progress. Transparently reporting the purpose of the research and the level
of rigour used in the design, execution, and analysis of the study enables readers to decide how
to use the research, whether the findings are groundbreaking and need to be confirmed before
building on them, or whether they are robust enough to be applied to other research settings.
To contextualise the importance of reporting information described in the Essential 10, this
document also covers experimental design concepts and best practices. This has two main pur-
poses: First, it helps authors understand the relevance of this information for readers to assess
the reliability of the reported results, thus encouraging thorough reporting. Second, it supports
the implementation of best practices in the design and conduct of animal research. Consulting
this document at the start of the process when planning an in vivo experiment will enable
researchers to make the best use of it, implement the advice on study design, and prepare for
the information that will need to be collected during the experiment to report the study in
adherence with the guidelines.
To ensure that the recommendations are as clear and useful as possible to the target audi-
ence, this document was road tested alongside the revised guidelines with researchers prepar-
ing manuscripts describing in vivo research [13]. Each item is written as a self-contained
section, enabling authors to refer to particular items independently, and a glossary (Box 1)
explains common statistical terms. Each subitem is also illustrated with examples of good
reporting from the published literature. Explanations and examples are also available from the
ARRIVE guidelines website: https://www.arriveguidelines.org.
Box 1. Glossary
Bias: The over- or underestimation of the true effect of an intervention. Bias is caused by
inadequacies in the design, conduct, or analysis of an experiment, resulting in the intro-
duction of error.
Descriptive and inferential statistics: Descriptive statistics are used to summarise the
data. They generally include a measure of central tendency (e.g., mean or median) and a
measure of spread (e.g., standard deviation or range). Inferential statistics are used to
make generalisations about the population from which the samples are drawn. Hypothe-
sis tests such as ANOVA, Mann-Whitney, or t tests are examples of inferential statistics.
Effect size: Quantitative measure of differences between groups, or strength of relation-
ships between variables.
Experimental unit: Biological entity subjected to an intervention independently of all
other units, such that it is possible to assign any two experimental units to different treat-
ment groups. Sometimes known as unit of randomisation.
External validity: Extent to which the results of a given study enable application or gen-
eralisation to other studies, study conditions, animal strains/species, or humans.
False negative: Statistically nonsignificant result obtained when the alternative hypothe-
sis (H1) is true. In statistics, it is known as the type II error.
PLOS BIOLOGY Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0
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ARRIVE Essential 10
The ARRIVE Essential 10 (Box 2) constitute the minimum reporting requirement to ensure
that reviewers and readers can assess the reliability of the findings presented. There is no rank-
ing within the set; items are presented in a logical order.
False positive: Statistically significant result obtained when the null hypothesis (H0) is
true. In statistics, it is known as the type I error.
Independent variable: Variable that either the researcher manipulates (treatment, con-
dition, time) or is a property of the sample (sex) or a technical feature (batch, cage, sam-
ple collection) that can potentially affect the outcome measure. Independent variables
can be scientifically interesting, or nuisance variables. Also known as predictor variable.
Internal validity: Extent to which the results of a given study can be attributed to the
effects of the experimental intervention, rather than some other, unknown factor(s)
(e.g., inadequacies in the design, conduct, or analysis of the study introducing bias).
Nuisance variable: Variables that are not of primary interest but should be considered
in the experimental design or the analysis because they may affect the outcome measure
and add variability. They become confounders if, in addition, they are correlated with an
independent variable of interest, as this introduces bias. Nuisance variables should be
considered in the design of the experiment (to prevent them from becoming confound-
ers) and in the analysis (to account for the variability and sometimes to reduce bias). For
example, nuisance variables can be used as blocking factors or covariates.
Null and alternative hypotheses: The null hypothesis (H0) is that there is no effect, such
as a difference between groups or an association between variables. The alternative
hypothesis (H1) postulates that an effect exists.
Outcome measure: Any variable recorded during a study to assess the effects of a
treatment or experimental intervention. Also known as dependent variable, response
variable.
Power: For a predefined, biologically meaningful effect size, the probability that the statis-
tical test will detect the effect if it exists (i.e., the null hypothesis is rejected correctly).
Sample size: Number of experimental units per group, also referred to as n.
Definitions are adapted from [14,15] and placed in the context of animal research.
Box 2. ARRIVE Essential 10
1. Study design
2. Sample size
3. Inclusion and exclusion criteria
4. Randomisation
PLOS BIOLOGY Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0
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Item 1. Study design
For each experiment, provide brief details of study design including:
1a. The groups being compared, including control groups. If no control group has been
used, the rationale should be stated.
Explanation. The choice of control or comparator group is dependent on the experimental
objective. Negative controls are used to determine whether a difference between groups is caused
by the intervention (e.g., wild-type animals versus genetically modified animals, placebo versus
active treatment, sham surgery versus surgical intervention). Positive controls can be used to
support the interpretation of negative results or determine if an expected effect is detectable.
It may not be necessary to include a separate control with no active treatment if, for exam-
ple, the experiment aims to compare a treatment administered by different methods (e.g.,
intraperitoneal administration versus oral gavage) or animals that are used as their own con-
trol in a longitudinal study. A pilot study, such as one designed to test the feasibility of a proce-
dure, might also not require a control group.
For complex study designs, a visual representation is more easily interpreted than a text
description, so a timeline diagram or flowchart is recommended. Diagrams facilitate the iden-
tification of which treatments and procedures were applied to specific animals or groups of
animals and at what point in the study these were performed. They also help to communicate
complex design features such as whether factors are crossed or nested (hierarchical/multilevel
designs), blocking (to reduce unwanted variation, see Item 4. Randomisation), or repeated
measurements over time on the same experimental unit (repeated measures designs); see [16–
18] for more information on different design types. The Experimental Design Assistant (EDA)
is a platform to support researchers in the design of in vivo experiments; it can be used to gen-
erate diagrams to represent any type of experimental design [19].
For each experiment performed, clearly report all groups used. Selectively excluding some
experimental groups (for example, because the data are inconsistent or conflict with the narra-
tive of the paper) is misleading and should be avoided [20]. Ensure that test groups, compara-
tors, and controls (negative or positive) can be identified easily. State clearly if the same
control group was used for multiple experiments or if no control group was used.
5. Blinding
6. Outcome measures
7. Statistical methods
8. Experimental animals
9. Experimental procedures
10. Results
Examples
Subitem 1a—Example 1
‘The DAV1 study is a one-way, two-period crossover trial with 16 piglets receiving
amoxicillin and placebo at period 1 and only amoxicillin at period 2. Amoxicillin was
administered orally with a single dose of 30 mg.kg-1. Plasma amoxicillin concentrations
PLOS BIOLOGY Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0
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1b. The experimental unit (e.g., a single animal, litter, or cage of animals).
Explanation. Within a design, biological and technical factors will often be organised hier-
archically, such as cells within animals and mitochondria within cells, or cages within rooms
and animals within cages. Such hierarchies can make determining the sample size difficult (is
it the number of animals, cells, or mitochondria?). The sample size is the number of experi-
mental units per group. The experimental unit is defined as the biological entity subjected to
an intervention independently of all other units, such that it is possible to assign any two
experimental units to different treatment groups. It is also sometimes called the unit of rando-
misation. In addition, the experimental units should not influence each other on the outcomes
that are measured.
Commonly, the experimental unit is the individual animal, each independently allocated to
a treatment group (e.g., a drug administered by injection). However, the experimental unit
may be the cage or the litter (e.g., a diet administered to a whole cage, or a treatment adminis-
tered to a dam and investigated in her pups), or it could be part of the animal (e.g., different
drug treatments applied topically to distinct body regions of the same animal). Animals may
also serve as their own controls, receiving different treatments separated by washout periods;
were collected at same sampling times at each period: 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 h’
[21].
Subitem 1a—Example 2
Fig 1. Reproduced from reference [22].
https://doi.org/10.1371/journal.pbio.3000411.g001
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here, the experimental unit is an animal for a period of time. There may also be multiple exper-
imental units in a single experiment, such as when a treatment is given to a pregnant dam and
then the weaned pups are allocated to different diets [23]. See [17,24,25] for further guidance
on identifying experimental units.
Conflating experimental units with subsamples or repeated measurements can lead to artifi-
cial inflation of the sample size. For example, measurements from 50 individual cells from a
single mouse represent n = 1 when the experimental unit is the mouse. The 50 measurements
are subsamples and provide an estimate of measurement error and so should be averaged or
used in a nested analysis. Reporting n = 50 in this case is an example of pseudoreplication [26].
It underestimates the true variability in a study, which can lead to false positives and invalidate
the analysis and resulting conclusions [26,27]. If, however, each cell taken from the mouse is
then randomly allocated to different treatments and assessed individually, the cell might be
regarded as the experimental unit.
Clearly indicate the experimental unit for each experiment so that the sample sizes and sta-
tistical analyses can be properly evaluated.
Item 2. Sample size
2a. Specify the exact number of experimental units allocated to each group, and the total
number in each experiment. Also indicate the total number of animals used.
Explanation. The sample size relates to the number of experimental units in each group at
the start of the study and is usually represented by n (see Item 1. Study design for further
Examples
Subitem 1b—Example 1
‘The present study used the tissues collected at E15.5 from dams fed the 1X choline and
4X choline diets (n = 3 dams per group, per fetal sex; total n = 12 dams). To ensure statis-
tical independence, only one placenta (either male or female) from each dam was used
for each experiment. Each placenta, therefore, was considered to be an experimental
unit’ [28].
Subitem 1b—Example 2
‘We have used data collected from high-throughput phenotyping, which is based on a
pipeline concept where a mouse is characterized by a series of standardized and vali-
dated tests underpinned by standard operating procedures (SOPs). . .. The individual
mouse was considered the experimental unit within the studies’ [29].
Subitem 1b—Example 3
‘Fish were divided in two groups according to weight (0.7–1.2 g and 1.3–1.7 g) and ran-
domly stocked (at a density of 15 fish per experimental unit) in 24 plastic tanks holding
60 L of water’ [30].
Subitem 1b—Example 4
‘In the study, n refers to number of animals, with five acquisitions from each [corticos-
triatal] slice, with a maximum of three slices obtained from each experimental animal
used for each protocol (six animals each group)’ [31].
PLOS BIOLOGY Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0
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guidance on identifying and reporting experimental units). This information is crucial to
assess the validity of the statistical model and the robustness of the experimental results.
The sample size in each group at the start of the study may be different from the n numbers
in the analysis (see Item 3. Inclusion and exclusion criteria); this information helps readers
identify attrition or if there have been exclusions and in which group they occurred. Reporting
the total number of animals used in the study is also useful to identify whether any were reused
between experiments.
Report the exact value of n per group and the total number in each experiment (including
any independent replications). If the experimental unit is not the animal, also report the total
number of animals to help readers understand the study design. For example, in a study inves-
tigating diet using cages of animals housed in pairs, the number of animals is double the num-
ber of experimental units.
2b. Explain how the sample size was decided. Provide details of any a priori sample size
calculation, if done.
Explanation. For any type of experiment, it is crucial to explain how the sample size was
determined. For hypothesis-testing experiments, in which inferential statistics are used to esti-
mate the size of the effect and to determine the weight of evidence against the null hypothesis,
the sample size needs to be justified to ensure experiments are of an optimal size to test the
research question [33,34] (see Item 13. Objectives). Sample sizes that are too small (i.e., under-
powered studies) produce inconclusive results, whereas sample sizes that are too large (i.e.,
overpowered studies) raise ethical issues over unnecessary use of animals and may produce triv-
ial findings that are statistically significant but not biologically relevant [35]. Low power has
three effects: first, within the experiment, real effects are more likely to be missed; second, when
an effect is detected, this will often be an overestimation of the true effect size [24]; and finally,
when low power is combined with publication bias, there is an increase in the false positive rate
Example
Subitem 2a –example 1
Fig 2. Reproduced from reference [32].
https://doi.org/10.1371/journal.pbio.3000411.g002
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in the published literature [36]. Consequently, low-powered studies contribute to the poor
internal validity of research and risk wasting animals used in inconclusive research [37].
Study design can influence the statistical power of an experiment, and the power calculation
used needs to be appropriate for the design implemented. Statistical programmes to help per-
form a priori sample size calculations exist for a variety of experimental designs and statistical
analyses, both freeware (web-based applets and functions in R) and commercial software [38–
40]. Choosing the appropriate calculator or algorithm to use depends on the type of outcome
measures and independent variables, and the number of groups. Consultation with a statisti-
cian is recommended, especially when the experimental design is complex or unusual.
When the experiment tests the effect of an intervention on the mean of a continuous out-
come measure, the sample size can be calculated a priori, based on a mathematical relationship
between the predefined, biologically relevant effect size, variability estimated from prior data,
chosen significance level, power, and sample size (see Box 3 and [17,41] for practical advice). If
you have used an a priori sample size calculation, report
• the analysis method (e.g., two-tailed Student t test with a 0.05 significance threshold)
• the effect size of interest and a justification explaining why an effect size of that magnitude is
relevant
• the estimate of variability used (e.g., standard deviation) and how it was estimated
• the power selected
Box 3. Information used in a power calculation
Sample size calculation is based on a mathematical relationship between the following
parameters: effect size, variability, significance level, power, and sample size. Questions
to consider are the following:
The primary objective of the experiment—What is the main outcome measure?
The primary outcome measure should be identified in the planning stage of the experi-
ment; it is the outcome of greatest importance, which will answer the main experimental
question.
The predefined effect size—What is a biologically relevant effect size?
The effect size is estimated as a biologically relevant change in the primary outcome
measure between the groups under study. This can be informed by similar studies and
involves scientists exploring what magnitude of effect would generate interest and would
be worth taking forward into further work. In preclinical studies, the clinical relevance
of the effect should also be taken into consideration.
What is the estimate of variability?
Estimates of variability can be obtained
• From data collected from a preliminary experiment conducted under identical condi-
tions to the planned experiment, e.g., a previous experiment in the same laboratory,
testing the same treatment under similar conditions on animals with the same
characteristics
PLOS BIOLOGY Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2.0
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There are several types of studies in which a priori sample size calculations are not appro-
priate. For example, the number of animals needed for antibody or tissue production is deter-
mined by the amount required and the production ability of an individual animal. For studies
in which the outcome is the successful generation of a sample or a condition (e.g., the produc-
tion of transgenic animals), the number of animals is determined by the probability of success
of the experimental procedure.
In early feasibility or pilot studies, the number of animals required depends on the pur-
pose of the study. When the objective of the preliminary study is primarily logistic or opera-
tional (e.g., to improve procedures and equipment), the number of animals needed is
generally small. In such cases, power calculations are not appropriate and sample sizes can
• From the control group in a previous experiment testing a different treatment
• From a similar experiment reported in the literature
Significance threshold—What risk of a false positive is acceptable?
The significance level or threshold (α) is the probability of obtaining a false positive. If it
is set at 0.05, then the risk of obtaining a false positive is 1 in 20 for a single statistical
test. However, the threshold or the p-values will need to be adjusted in scenarios of mul-
tiple testing (e.g., by using a Bonferroni correction).
Power—What risk of a false negative is acceptable?
For a predefined, biologically meaningful effect size, the power (1 − β) is the probability
that the statistical test will detect the effect if it genuinely exists (i.e., true positive result).
A target power between 80% and 95% is normally deemed acceptable, which entails a
risk of false negative between 5% and 20%.
Directionality—Will you use a one- or two-sided test?
The directionality of a test depends on the distribution of the test statistics for a given
analysis. For tests based on t or z distributions (such as t tests), whether the data will be
analysed using a one- or two-sided test relates to whether the alternative hypothesis is
directional or not. An experiment with a directional (one-sided) alternative hypothesis
can be powered and analysed with a one-sided test with the goal of maximising the sensi-
tivity to detect this directional effect. Controversy exists within the statistics community
on when it is appropriate to use a one-sided test [42]. The use of a one-sided test requires
justification of why a treatment effect is only of interest when it is in a defined direction
and why they would treat a large effect in the unexpected direction no differently from a
nonsignificant difference [43]. Following the use of a one-sided test, the investigator can-
not then test for the possibility of missing an effect in the untested direction. Choosing a
one-tailed test for the sole purpose of attaining statistical significance is not appropriate.
Two-sided tests with a nondirectional alternative hypothesis are much more common
and allow researchers to detect the effect of a treatment regardless of its direction.
Note that analyses such as ANOVA and chi-squared are based on asymmetrical distribu-
tions (F-distribution and chi-squared distribution) with only one tail. Therefore, these
tests do not have a directionality option.
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be estimated based on operational capacity and constraints [44]. Pilot studies alone are
unlikely to provide adequate data on variability for a power calculation for future experi-
ments. Systematic reviews and previous studies are more appropriate sources of information
on variability [45].
If no power calculation was used to determine the sample size, state this explicitly and
provide the reasoning that was used to decide on the sample size per group. Regardless of
whether a power calculation was used or not, when explaining how the sample size was
determined take into consideration any anticipated loss of animals or data, for example,
due to exclusion criteria established upfront or expected attrition (see Item 3. Inclusion and
exclusion criteria).
Item 3. Inclusion and exclusion criteria
3a. Describe any criteria used for including or excluding animals (or experimental units)
during the experiment, and data points during the analysis. Specify if these criteria were
established a priori. If no criteria were set, state this explicitly.
Explanation. Inclusion and exclusion criteria define the eligibility or disqualification of
animals and data once the study has commenced. To ensure scientific rigour, the criteria
should be defined before the experiment starts and data are collected [8,33,48,49]. Inclusion
criteria should not be confused with animal characteristics (see Item 8. Experimental animals)
but can be related to these (e.g., body weights must be within a certain range for a particular
procedure) or related to other study parameters (e.g., task performance has to exceed a given
threshold). In studies in which selected data are reanalysed for a different purpose, inclusion
and exclusion criteria should describe how data were selected.
Exclusion criteria may result from technical or welfare issues such as complications
anticipated during surgery or circumstances in which test procedures might be compro-
mised (e.g., development of motor impairments that could affect behavioural measure-
ments). Criteria for excluding samples or data include failure to meet quality control
Examples
Subitem 2b—Example 1
‘The sample size calculation was based on postoperative pain numerical rating scale
(NRS) scores after administration of buprenorphine (NRS AUC mean = 2.70; noninfer-
iority limit = 0.54; standard deviation = 0.66) as the reference treatment. . . and also
Glasgow Composite Pain Scale (GCPS) scores. . . using online software (Experimental
design assistant; https://eda.nc3rs.org.uk/eda/login/auth). The power of the experiment
was set to 80%. A total of 20 dogs per group were considered necessary’ [46].
Subitem 2b—Example 2
‘We selected a small sample size because the bioglass prototype was evaluated in vivo for
the first time in the present study, and therefore, the initial intention was to gather basic
evidence regarding the use of this biomaterial in more complex experimental designs’
[47].
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standards, such as insufficient sample volumes, unacceptable levels of contaminants, poor
histological quality, etc. Similarly, how the researcher will define and handle data outliers
during the analysis should also be decided before the experiment starts (see subitem 3b for
guidance on responsible data cleaning).
Exclusion criteria may also reflect the ethical principles of a study in line with its humane
endpoints (see Item 16. Animal care and monitoring). For example, in cancer studies, an ani-
mal might be dropped from the study and euthanised before the predetermined time point if
the size of a subcutaneous tumour exceeds a specific volume [50]. If losses are anticipated,
these should be considered when determining the number of animals to include in the study
(see Item 2. Sample size). Whereas exclusion criteria and humane endpoints are typically
included in the ethical review application, reporting the criteria used to exclude animals or
data points in the manuscript helps readers with the interpretation of the data and provides
crucial information to other researchers wanting to adopt the model.
Best practice is to include all a priori inclusion and exclusion/outlier criteria in a preregis-
tered protocol (see Item 19. Protocol registration). At the very least, these criteria should be
documented in a laboratory notebook and reported in manuscripts, explicitly stating that the
criteria were defined before any data was collected.
3b. For each experimental group, report any animals, experimental units, or data points
not included in the analysis and explain why. If there were no exclusions, state so.
Explanation. Animals, experimental units, or data points that are unaccounted for can lead
to instances in which conclusions cannot be supported by the raw data [52]. Reporting exclu-
sions and attritions provides valuable information to other investigators evaluating the results
or who intend to repeat the experiment or test the intervention in other species. It may also
provide important safety information for human trials (e.g., exclusions related to adverse
effects).
There are many legitimate reasons for experimental attrition, some of which are anticipated
and controlled for in advance (see subitem 3a on defining exclusion and inclusion criteria),
but some data loss might not be anticipated. For example, data points may be excluded from
analyses because of an animal receiving the wrong treatment, unexpected drug toxicity, infec-
tions or diseases unrelated to the experiment, sampling errors (e.g., a malfunctioning assay
that produced a spurious result, inadequate calibration of equipment), or other human error
(e.g., forgetting to switch on equipment for a recording).
Example
Subitem 3a—Example 1
‘The animals were included in the study if they underwent successful MCA occlusion
(MCAo), defined by a 60% or greater drop in cerebral blood flow seen with laser Dopp-
ler flowmetry. The animals were excluded if insertion of the thread resulted in perfora-
tion of the vessel wall (determined by the presence of sub-arachnoid blood at the time of
sacrifice), if the silicon tip of the thread became dislodged during withdrawal, or if the
animal died prematurely, preventing the collection of behavioral and histological data’
[51].
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Most statistical analysis methods are extremely sensitive to outliers and missing data. In
some instances, it may be scientifically justifiable to remove outlying data points from an
analysis, such as obvious errors in data entry or measurement with readings that are outside
a plausible range. Inappropriate data cleaning has the potential to bias study outcomes [53];
providing the reasoning for removing data points enables the distinction to be made between
responsible data cleaning and data manipulation. Missing data, common in all areas of
research, can impact the sensitivity of the study and also lead to biased estimates, distorted
power, and loss of information if the missing values are not random [54]. Analysis plans
should include methods to explore why data are missing. It is also important to consider and
justify analysis methods that account for missing data [55,56].
There is a movement toward greater data sharing (see Item 20. Data access), along with an
increase in strategies such as code sharing to enable analysis replication. These practices, how-
ever transparent, still need to be accompanied by a disclosure on the reasoning for data clean-
ing and whether methods were defined before any data were collected.
Report all animal exclusions and loss of data points, along with the rationale for their exclu-
sion. For example, this information can be summarised as a table or a flowchart describing
attrition in each treatment group. Accompanying this information should be an explicit
description of whether researchers were blinded to the group allocations when data or animals
were excluded (see Item 5. Blinding and [57]). Explicitly state when built-in models in statistics
packages have been used to remove outliers (e.g., GraphPad Prism’s outlier test).
Examples
Subitem 3b—Example 1
‘Pen was the experimental unit for all data. One entire pen (ZnAA90) was removed as an
outlier from both Pre-RAC and RAC periods for poor performance caused by illness
unrelated to treatment. . .. Outliers were determined using Cook’s D statistic and
removed if Cook’s D > 0.5. One steer was determined to be an outlier for day 48 liver
biopsy TM and data were removed’ [58].
Subitem 3b—Example 2
‘Seventy-two SHRs were randomized into the study, of which 13 did not meet our inclu-
sion and exclusion criteria because the drop in cerebral blood flow at occlusion did not
reach 60% (seven animals), postoperative death (one animal: autopsy unable to identify
the cause of death), haemorrhage during thread insertion (one animal), and disconnec-
tion of the silicon tip of the thread during withdrawal, making the permanence of reper-
fusion uncertain (four animals). A total of 59 animals were therefore included in the
analysis of infarct volume in this study. In error, three animals were sacrificed before
their final assessment of neurobehavioral score: one from the normothermia/water
group and two from the hypothermia/pethidine group. These errors occurred blinded to
treatment group allocation. A total of 56 animals were therefore included in the analysis
of neurobehavioral score’ [51].
Subitem 3b—Example 3
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3c. For each analysis, report the exact value of n in each experimental group.
Explanation. The exact number of experimental units analysed in each group (i.e., the n
number) is essential information for the reader to interpret the analysis; it should be reported
unambiguously. All animals and data used in the experiment should be accounted for in the
Fig 3. Reproduced from reference [59].
https://doi.org/10.1371/journal.pbio.3000411.g003
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data presented. Sometimes, for good reasons, animals may need to be excluded from a study
(e.g., illness or mortality), or data points excluded from analyses (e.g., biologically implausible
values). Reporting losses will help the reader to understand the experimental design process,
replicate methods, and provide adequate tracking of animal numbers in a study, especially
when sample size numbers in the analyses do not match the original group numbers.
For each outcome measure, indicate numbers clearly within the text or on figures and pro-
vide absolute numbers (e.g., 10/20, not 50%). For studies in which animals are measured at dif-
ferent time points, explicitly report the full description of which animals undergo measurement
and when [33].
Item 4. Randomisation
4a. State whether randomisation was used to allocate experimental units to control and treat-
ment groups. If done, provide the method used to generate the randomisation sequence.
Explanation. Using appropriate randomisation methods during the allocation to groups
ensures that each experimental unit has an equal probability of receiving a particular treatment
and provides balanced numbers in each treatment group. Selecting an animal ‘at random’ (i.e.,
haphazardly or arbitrarily) from a cage is not statistically random, as the process involves
human judgement. It can introduce bias that influences the results, as a researcher may (con-
sciously or subconsciously) make judgements in allocating an animal to a particular group, or
because of unknown and uncontrolled differences in the experimental conditions or animals
in different groups. Using a validated method of randomisation helps minimise selection bias
and reduce systematic differences in the characteristics of animals allocated to different groups
[62–64]. Inferential statistics based on nonrandomised group allocation are not valid [65,66].
Thus, the use of randomisation is a prerequisite for any experiment designed to test a
Examples
Subitem 3c—Example 1
‘Group F contained 29 adult males and 58 adult females in 2010 (n = 87), and 32 adult
males and 66 adult females in 2011 (n = 98). The increase in female numbers was due to
maturation of juveniles to adults. Females belonged to three matrilines, and there were
no major shifts in rank in the male hierarchy. Six mid to low ranking individuals died
and were excluded from analyses, as were five mid-ranking males who emigrated from
the group at the beginning of 2011’ [60].
Subitem 3c—Example 2
‘The proportion of test time that animals spent interacting with the handler (sniffed the
gloved hand or tunnel, made paw contact, climbed on, or entered the handling tunnel)
was measured from DVD recordings. This was then averaged across the two mice in
each cage as they were tested together and their behaviour was not independent. . .. Mice
handled with the home cage tunnel spent a much greater proportion of the test interact-
ing with the handler (mean ± s.e.m., 39.8 ± 5.2 percent time of 60 s test, n = 8 cages)
than those handled by tail (6.4 ± 2.0 percent time, n = 8 cages), while those handled by
cupping showed intermediate levels of voluntary interaction (27.6 ± 7.1 percent time,
n = 8 cages)’ [61].
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hypothesis. Examples of appropriate randomisation methods include online random number
generators (e.g., https://www.graphpad.com/quickcalcs/randomize1/) or a function like Rand
() in spreadsheet software such as Excel, Google Sheets, or LibreOffice. The EDA has a dedi-
cated feature for randomisation and allocation concealment [19].
Systematic reviews have shown that animal experiments that do not report randomisation
or other bias-reducing measures such as blinding are more likely to report exaggerated effects
that meet conventional measures of statistical significance [67–69]. It is especially important to
use randomisation in situations in which it is not possible to blind all or parts of the experi-
ment, but even with randomisation, researcher bias can pervert the allocation. This can be
avoided by using allocation concealment (see Item 5. Blinding). In studies in which sample
sizes are small, simple randomisation may result in unbalanced groups; here, randomisation
strategies to balance groups such as randomising in matched pairs [70–72] and blocking are
encouraged [17]. Reporting the precise method used to allocate animals or experimental units
to groups enables readers to assess the reliability of the results and identify potential
limitations.
Report the type of randomisation used (simple, stratified, randomised complete blocks,
etc.; see Box 4), the method used to generate the randomisation sequence (e.g., computer-gen-
erated randomisation sequence, with details of the algorithm or programme used), and what
was randomised (e.g., treatment to experimental unit, order of treatment for each animal). If
this varies between experiments, report this information specifically for each experiment. If
randomisation was not the method used to allocate experimental units to groups, state this
explicitly and explain how the groups being compared were formed.
Box 4. Considerations for the randomisation strategy
Simple randomisation
All animals/samples are simultaneously randomised to the treatment groups without
considering any other variable. This strategy is rarely appropriate, as it cannot ensure
that comparison groups are balanced for other variables that might influence the result
of an experiment.
Randomisation within blocks
Blocking is a method of controlling natural variation among experimental units. This
splits up the experiment into smaller subexperiments (blocks), and treatments are ran-
domised to experimental units within each block [17,66,73]. This takes into account nui-
sance variables that could potentially bias the results (e.g., cage location, day or week of
procedure).
Stratified randomisation uses the same principle as randomisation within blocks, only
the strata tend to be traits of the animal that are likely to be associated with the response
(e.g., weight class or tumour size class). This can lead to differences in the practical
implementation of stratified randomisation as compared with block randomisation (e.g.,
there may not be equal numbers of experimental units in each weight class).
Other randomisation strategies
Minimisation is an alternative strategy to allocate animals/samples to treatment group to
balance variables that might influence the result of an experiment. With minimisation,
the treatment allocated to the next animal/sample depends on the characteristics of
those animals/samples already assigned. The aim is that each allocation should minimise
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the imbalance across multiple factors [74]. This approach works well for a continuous
nuisance variable such as body weight or starting tumour volume.
Examples of nuisance variables that can be accounted for in the randomisation strategy
• Time or day of the experiment
• Litter, cage, or fish tank
• Investigator or surgeon—different level of experience in the people administering the
treatments, performing the surgeries, or assessing the results may result in varying
stress levels in the animals or duration of anaesthesia
• Equipment (e.g., PCR machine, spectrophotometer)—calibration may vary
• Measurement of a study parameter (e.g., initial tumour volume)
• Animal characteristics (e.g., sex, age bracket, weight bracket)
• Location—exposure to light, ventilation, and disturbances may vary in cages located at
different height or on different racks, which may affect important physiological
processes
Implication for the analysis
If blocking factors are used in the randomisation, they should also be included in the anal-
ysis. Nuisance variables increase variability in the sample, which reduces statistical power.
Including a nuisance variable as a blocking factor in the analysis accounts for that vari-
ability and can increase the power, thus increasing the ability to detect a real effect with
fewer experimental units. However, blocking uses up degrees of freedom and thus reduces
the power if the nuisance variable does not have a substantial impact on variability.
Examples
Subitem 4a—Example 1
‘Fifty 12-week-old male Sprague-Dawley rats, weighing 320–360g, were obtained from
Guangdong Medical Laboratory Animal Center (Guangzhou, China) and randomly
divided into two groups (25 rats/group): the intact group and the castration group.
Random numbers were generated using the standard = RAND() function in Microsoft
Excel’ [75].
Subitem 4a—Example 2
‘Animals were randomized after surviving the initial I/R, using a computer based ran-
dom order generator’ [76].
Subitem 4a—Example 3
‘At each institute, phenotyping data from both sexes is collected at regular intervals on
age-matched wildtype mice of equivalent genetic backgrounds. Cohorts of at least seven
homozygote mice of each sex per pipeline were generated. . .. The random allocation of
mice to experimental group (wildtype versus knockout) was driven by Mendelian Inher-
itance’ [29].
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4b. Describe the strategy used to minimise potential confounders such as the order of
treatments and measurements, or animal/cage location. If confounders were not con-
trolled, state this explicitly.
Explanation. Ensuring there is no systematic difference between animals in different
groups apart from the experimental exposure is an important principle throughout the con-
duct of the experiment. Identifying nuisance variables (sources of variability or conditions that
could potentially bias results) and managing them in the design and analysis increases the sen-
sitivity of the experiment. For example, rodents in cages at the top of the rack may be exposed
to higher light levels, which can affect stress [77].
Reporting the strategies implemented to minimise potential differences that arise between
treatment groups during the course of the experiment enables others to assess the internal
validity. Strategies to report include standardising (keeping conditions the same, e.g., all sur-
geries done by the same surgeon), randomising (e.g., the sampling or measurement order),
and blocking or counterbalancing (e.g., position of animal cages or tanks on the rack), to
ensure groups are similarly affected by a source of variability. In some cases, practical
constraints prevent some nuisance variables from being randomised, but they can still be
accounted for in the analysis (see Item 7. Statistical methods).
Report the methods used to minimise confounding factors alongside the methods used to
allocate animals to groups. If no measures were used to minimise confounders (e.g., treatment
order, measurement order, cage or tank position on a rack), explicitly state this and explain
why.
Examples
Subitem 4b—Example 1
‘Randomisation was carried out as follows. On arrival from El-Nile Company, animals
were assigned a group designation and weighed. A total number of 32 animals were
divided into four different weight groups (eight animals per group). Each animal was
assigned a temporary random number within the weight range group. On the basis of
their position on the rack, cages were given a numerical designation. For each group, a
cage was selected randomly from the pool of all cages. Two animals were removed from
each weight range group and given their permanent numerical designation in the cages.
Then, the cages were randomized within the exposure group’ [78].
Subitem 4b—Example 2
‘. . . test time was between 08.30am to 12.30pm and testing order was randomized daily,
with each animal tested at a different time each test day’ [79].
Subitem 4b—Example 3
‘Bulls were blocked by BW into four blocks of 905 animals with similar BW and then
within each block, bulls were randomly assigned to one of four experimental treat-
ments in a completely randomized block design resulting in 905 animals per treatment.
Animals were allocated to 20 pens (181 animals per pen and five pens per treatment)’
[80].
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Item 5. Blinding
Describe who was aware of the group allocation at the different stages of the experiment
(during the allocation, the conduct of the experiment, the outcome assessment, and the
data analysis).
Explanation. Researchers often expect a particular outcome and can unintentionally influ-
ence the experiment or interpret the data in such a way as to support their preferred hypothesis
[81]. Blinding is a strategy used to minimise these subjective biases.
Although there is primary evidence of the impact of blinding in the clinical literature that
directly compares blinded versus unblinded assessment of outcomes [82], there is limited
empirical evidence in animal research [83,84]. There are, however, compelling data from sys-
tematic reviews showing that nonblinded outcome assessment leads to the treatment effects
being overestimated, and the lack of bias-reducing measures such as randomisation and blind-
ing can contribute to as much as 30%–45% inflation of effect sizes [67,68,85].
Ideally, investigators should be unaware of the treatment(s) animals have received or will be
receiving, from the start of the experiment until the data have been analysed. If this is not pos-
sible for every stage of an experiment (see Box 5), it should always be possible to conduct at
least some of the stages blind. This has implications for the organisation of the experiment and
may require help from additional personnel—for example, a surgeon to perform interventions,
a technician to code the treatment syringes for each animal, or a colleague to code the treat-
ment groups for the analysis. Online resources are available to facilitate allocation concealment
and blinding [19].
Box 5. Blinding during different stages of an experiment
During allocation
Allocation concealment refers to concealing the treatment to be allocated to each indi-
vidual animal from those assigning the animals to groups, until the time of assignment.
Together with randomisation, allocation concealment helps minimise selection bias,
which can introduce systematic differences between treatment groups.
During the conduct of the experiment
When possible, animal care staff and those who administer treatments should be
unaware of allocation groups to ensure that all animals in the experiment are handled,
monitored, and treated in the same way. Treating different groups differently based on
the treatment they have received could alter animal behaviour and physiology and pro-
duce confounds.
Welfare or safety reasons may prevent blinding of animal care staff, but in most cases,
blinding is possible. For example, if hazardous microorganisms are used, control animals
can be considered as dangerous as infected animals. If a welfare issue would only be tol-
erated for a short time in treated but not control animals, a harm-benefit analysis is
needed to decide whether blinding should be used.
During the outcome assessment
The person collecting experimental measurements or conducting assessments should not
know which treatment each sample/animal received and which samples/animals are
grouped together. Blinding is especially important during outcome assessment, particularly
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Specify whether blinding was used or not for each step of the experimental process (see
Box 5) and indicate what particular treatment or condition the investigators were blinded to,
or aware of.
If blinding was not used at any of the steps outlined in Box 5, explicitly state this and pro-
vide the reason why blinding was not possible or not considered.
if there is a subjective element (e.g., when assessing behavioural changes or reading histo-
logical slides) [83]. Randomising the order of examination can also reduce bias.
If the person assessing the outcome cannot be blinded to the group allocation (e.g., obvi-
ous phenotypic or behavioural differences between groups), some, but not all, of the
sources of bias could be mitigated by sending data for analysis to a third party who has
no vested interest in the experiment and does not know whether a treatment is expected
to improve or worsen the outcome.
During the data analysis
The person analysing the data should know which data are grouped together to enable
group comparisons but should not be aware of which specific treatment each group
received. This type of blinding is often neglected but is important, as the analyst makes
many semisubjective decisions such as applying data transformation to outcome mea-
sures, choosing methods for handling missing data, and handling outliers. How these
decisions will be made should also be decided a priori.
Data can be coded prior to analysis so that the treatment group cannot be identified
before analysis is completed.
Examples
Item 5—Example 1
‘For each animal, four different investigators were involved as follows: a first investigator
(RB) administered the treatment based on the randomization table. This investigator
was the only person aware of the treatment group allocation. A second investigator (SC)
was responsible for the anaesthetic procedure, whereas a third investigator (MS, PG, IT)
performed the surgical procedure. Finally, a fourth investigator (MAD) (also unaware of
treatment) assessed GCPS and NRS, mechanical nociceptive threshold (MNT), and
sedation NRS scores’ [46].
Item 5—Example 2
‘. . . due to overt behavioral seizure activity the experimenter could not be blinded to
whether the animal was injected with pilocarpine or with saline’ [86].
Item 5—Example 3
‘Investigators could not be blinded to the mouse strain due to the difference in coat col-
ors, but the three-chamber sociability test was performed with ANY-maze video tracking
software (Stoelting, Wood Dale, IL, USA) using an overhead video camera system to
automate behavioral testing and provide unbiased data analyses. The one-chamber social
interaction test requires manual scoring and was analyzed by an individual with no
knowledge of the questions’ [87].
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Item 6. Outcome measures
6a. Clearly define all outcome measures assessed (e.g., cell death, molecular markers, or
behavioural changes).
Explanation. An outcome measure (also known as a dependent variable or a response vari-
able) is any variable recorded during a study (e.g., volume of damaged tissue, number of dead
cells, specific molecular marker) to assess the effects of a treatment or experimental interven-
tion. Outcome measures may be important for characterising a sample (e.g., baseline data) or
for describing complex responses (e.g., ‘haemodynamic’ outcome measures including heart
rate, blood pressure, central venous pressure, and cardiac output). Failure to disclose all the
outcomes that were measured introduces bias in the literature, as positive outcomes (e.g.,
those statistically significant) are reported more often [88–91].
Explicitly describe what was measured, especially when measures can be operationalised in
different ways. For example, activity could be recorded as time spent moving or distance trav-
elled. When possible, the recording of outcome measures should be made in an unbiased man-
ner (e.g., blinded to the treatment allocation of each experimental group; see Item 5. Blinding).
Specify how the outcome measure(s) assessed are relevant to the objectives of the study.
6b. For hypothesis-testing studies, specify the primary outcome measure, i.e., the out-
come measure that was used to determine the sample size.
Explanation. In a hypothesis-testing experiment, the primary outcome measure answers
the main biological question. It is the outcome of greatest importance, identified in the plan-
ning stages of the experiment and used as the basis for the sample size calculation (see Box 3).
For exploratory studies, it is not necessary to identify a single primary outcome, and often
multiple outcomes are assessed (see Item 13. Objectives).
In a hypothesis-testing study powered to detect an effect on the primary outcome measure,
data on secondary outcomes are used to evaluate additional effects of the intervention, but sub-
sequent statistical analysis of secondary outcome measures may be underpowered, making
results and interpretation less reliable [88,93]. Studies that claim to test a hypothesis but do not
specify a predefined primary outcome measure or those that change the primary outcome
measure after data were collected (also known as primary outcome switching) are liable to
selectively report only statistically significant results, favouring more positive findings [94].
Registering a protocol in advance protects the researcher against concerns about selective
outcome reporting (also known as data dredging or p-hacking) and provides evidence that the
primary outcome reported in the manuscript accurately reflects what was planned [95] (see
Item 19. Protocol registration).
Example
Subitem 6a—Example 1
‘The following parameters were assessed: threshold pressure (TP; intravesical pressure
immediately before micturition); post-void pressure (PVP; intravesical pressure imme-
diately after micturition); peak pressure (PP; highest intravesical pressure during
micturition); capacity (CP; volume of saline needed to induce the first micturition);
compliance (CO; CP to TP ratio); frequency of voiding contractions (VC) and frequency
of non-voiding contractions (NVCs)’ [92].
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In studies using inferential statistics to test a hypothesis (e.g., t test, ANOVA), if more than
one outcome was assessed, explicitly identify the primary outcome measure, state whether it
was defined as such prior to data collection and whether it was used in the sample size calcula-
tion. If there was no primary outcome measure, explicitly state so.
Item 7. Statistical methods
7a. Provide details of the statistical methods used for each analysis, including software used.
Explanation. The statistical analysis methods implemented will reflect the goals and the
design of the experiment; they should be decided in advance before data are collected (see
Item 19. Protocol registration). Both exploratory and hypothesis-testing studies might use
descriptive statistics to summarise the data (e.g., mean and SD, or median and range). In
exploratory studies in which no specific hypothesis was tested, reporting descriptive statistics
is important for generating new hypotheses that may be tested in subsequent experiments, but
it does not allow conclusions beyond the data. In addition to descriptive statistics, hypothesis-
testing studies might use inferential statistics to test a specific hypothesis.
Reporting the analysis methods in detail is essential to ensure readers and peer reviewers
can assess the appropriateness of the methods selected and judge the validity of the output.
The description of the statistical analysis should provide enough detail so that another
researcher could reanalyse the raw data using the same method and obtain the same results.
Make it clear which method was used for which analysis.
Analysing the data using different methods and selectively reporting those with statisti-
cally significant results constitutes p-hacking and introduces bias in the literature [90,94].
Report all analyses performed in full. Relevant information to describe the statistical meth-
ods include
Examples
Subitem 6b—Example 1
‘The primary outcome of this study will be forelimb function assessed with the staircase
test. Secondary outcomes constitute Rotarod performance, stroke volume (quantified on
MR imaging or brain sections, respectively), diffusion tensor imaging (DTI) connectome
mapping, and histological analyses to measure neuronal and microglial densities, and
phagocytic activity. . .. The study is designed with 80% power to detect a relative 25% dif-
ference in pellet-reaching performance in the Staircase test’ [96].
Subitem 6b—Example 2
‘The primary endpoint of this study was defined as left ventricular ejection fraction (EF)
at the end of follow-up, measured by magnetic resonance imaging (MRI). Secondary
endpoints were left ventricular end diastolic volume and left ventricular end systolic vol-
ume (EDV and ESV) measured by MRI, infarct size measured by ex vivo gross macro-
scopy after incubation with triphenyltetrazolium chloride (TTC) and late gadolinium
enhancement (LGE) MRI, functional parameters serially measured by pressure volume
(PV-)loop and echocardiography, coronary microvascular function by intracoronary
pressure- and flow measurements and vascular density and fibrosis on histology’ [76].
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• the outcome measures
• the independent variables of interest
• the nuisance variables taken into account in each statistical test (e.g., as blocking factors or
covariates)
• what statistical analyses were performed and references for the methods used
• how missing values were handled
• adjustment for multiple comparisons
• the software package and version used, including computer code if available [97]
The outcome measure is potentially affected by the treatments or interventions being
tested but also by other factors, such as the properties of the biological samples (sex, litter, age,
weight, etc.) and technical considerations (cage, time of day, batch, experimenter, etc.). To
reduce the risk of bias, some of these factors can be taken into account in the design of the
experiment, for example, by using blocking factors in the randomisation (see Item 4. Rando-
misation). Factors deemed to affect the variability of the outcome measure should also be han-
dled in the analysis, for example, as a blocking factor (e.g., batch of reagent or experimenter)
or as a covariate (e.g., starting tumour size at point of randomisation).
Furthermore, to conduct the analysis appropriately, it is important to recognise the hierar-
chy that can exist in an experiment. The hierarchy can induce a clustering effect; for example,
cage, litter, or animal effects can occur when the outcomes measured for animals from the
same cage/litter, or for cells from the same animal, are more similar to each other. This rela-
tionship has to be managed in the statistical analysis by including cage/litter/animal effects
in the model or by aggregating the outcome measure to the cage/litter/animal level. Thus,
describing the reality of the experiment and the hierarchy of the data, along with the measures
taken in the design and the analysis to account for this hierarchy, is crucial to assessing
whether the statistical methods used are appropriate.
For bespoke analysis—for example, regression analysis with many terms—it is essential to
describe the analysis pipeline in detail. This could include detailing the starting model and any
model simplification steps.
When reporting descriptive statistics, explicitly state which measure of central tendency is
reported (e.g., mean or median) and which measure of variability is reported (e.g., standard
deviation, range, quartiles, or interquartile range). Also describe any modification made to the
raw data before analysis (e.g., relative quantification of gene expression against a housekeeping
gene). For further guidance on statistical reporting, refer to the Statistical Analyses and Meth-
ods in the Published Literature (SAMPL) guidelines [98].
Examples
Subitem 7a—Example 1
‘Analysis of variance was performed using the GLM procedure of SAS (SAS Inst., Cary,
NC). Average pen values were used as the experimental unit for the performance param-
eters. The model considered the effects of block and dietary treatment (5 diets). Data
were adjusted by the covariant of initial body weight. Orthogonal contrasts were used to
test the effects of SDPP processing (UV vs no UV) and dietary SDPP level (3% vs 6%).
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7b. Describe any methods used to assess whether the data met the assumptions of the
statistical approach, and what was done if the assumptions were not met.
Explanation. Hypothesis tests are based on assumptions about the underlying data.
Describing how assumptions were assessed and whether these assumptions are met by the data
enables readers to assess the suitability of the statistical approach used. If the assumptions are
incorrect, the conclusions may not be valid. For example, the assumptions for data used in
parametric tests (such as a t test, z test, ANOVA, etc.) are that the data are continuous, the
residuals from the analysis are normally distributed, the responses are independent, and differ-
ent groups have similar variances.
There are various tests for normality, for example, the Shapiro-Wilk and Kolmogorov-
Smirnov tests. However, these tests have to be used cautiously. If the sample size is small, they
will struggle to detect non-normality; if the sample size is large, the tests will detect unimpor-
tant deviations. An alternative approach is to evaluate data with visual plots, e.g., normal prob-
ability plots, box plots, scatterplots. If the residuals of the analysis are not normally distributed,
the assumption may be satisfied using a data transformation in which the same mathematical
function is applied to all data points to produce normally distributed data (e.g., loge, log10,
square root).
Other types of outcome measures (binary, categorical, or ordinal) will require different
methods of analysis, and each will have different sets of assumptions. For example, categorical
data are summarised by counts and percentages or proportions and are analysed by tests of
proportions; these analysis methods assume that data are binary, ordinal or nominal, and inde-
pendent [18].
For each statistical test used (parametric or nonparametric), report the type of outcome
measure and the methods used to test the assumptions of the statistical approach. If data were
transformed, identify precisely the transformation used and which outcome measures it was
applied to. Report any changes to the analysis if the assumptions were not met and an
Results are presented as least squares means. The level of significance was set at
P < 0.05’ [99].
Subitem 7a—Example 2
‘All risk factors of interest were investigated in a single model. Logistic regression allows
blocking factors and explicitly investigates the effect of each independent variable con-
trolling for the effects of all others. . .. As we were interested in husbandry and environ-
mental effects, we blocked the analysis by important biological variables (age; backstrain;
inbreeding; sex; breeding status) to control for their effect. (The role of these biological
variables in barbering behavior, particularly with reference to barbering as a model for
the human disorder trichotillomania, is described elsewhere . . .). We also blocked by
room to control for the effect of unknown environmental variables associated with this
design variable. We tested for the effect of the following husbandry and environmental
risk factors: cage mate relationships (i.e. siblings, non-siblings, or mixed); cage type (i.e.
plastic or steel); cage height from floor; cage horizontal position (whether the cage was
on the side or the middle of a rack); stocking density; and the number of adults in the
cage. Cage material by cage height from floor; and cage material by cage horizontal posi-
tion interactions were examined, and then removed from the model as they were nonsig-
nificant. N = 1959 mice were included in this analysis’ [100].
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alternative approach was used (e.g., a nonparametric test was used, which does not require the
assumption of normality). If the relevant assumptions about the data were not tested, state this
explicitly.
Item 8. Experimental animals
8a. Provide species-appropriate details of the animals used, including species, strain and
substrain, sex, age or developmental stage, and, if relevant, weight.
Explanation. The species, strain, substrain, sex, weight, and age of animals are critical fac-
tors that can influence most experimental results [103–107]. Reporting the characteristics of
all animals used is equivalent to standardised human patient demographic data; these data sup-
port both the internal and external validity of the study results. It enables other researchers to
repeat the experiment and generalise the findings. It also enables readers to assess whether the
animal characteristics chosen for the experiment are relevant to the research objectives.
When reporting age and weight, include summary statistics for each experimental group
(e.g., mean and standard deviation) and, if possible, baseline values for individual animals
(e.g., as supplementary information or a link to a publicly accessible data repository). As
body weight might vary during the course of the study, indicate when the measurements were
taken. For most species, precise reporting of age is more informative than a description of the
developmental status (e.g., a mouse referred to as an adult can vary in age from 6 to 20 weeks
[108]). In some cases, however, reporting the developmental stage is more informative than
chronological age—for example, in juvenile Xenopus, in which rate of development can be
manipulated by incubation temperature [109].
Reporting the weight or the sex of the animals used may not feasible for all studies. For
example, sex may be unknown for embryos or juveniles, or weight measurement may be par-
ticularly stressful for some aquatic species. If reporting these characteristics can be reasonably
expected for the species used and the experimental setting but are not reported, provide a
justification.
Examples
Subitem 7b—Example 1
‘Model assumptions were checked using the Shapiro-Wilk normality test and Levene’s
Test for homogeneity of variance and by visual inspection of residual and fitted value
plots. Some of the response variables had to be transformed by applying the natural loga-
rithm or the second or third root, but were back-transformed for visualization of signifi-
cant effects’ [101].
Subitem 7b—Example 2
‘The effects of housing (treatment) and day of euthanasia on cortisol levels were assessed
by using fixed-effects 2-way ANOVA. An initial exploratory analysis indicated that
groups with higher average cortisol levels also had greater variation in this response vari-
able. To make the variation more uniform, we used a logarithmic transform of each
fish’s cortisol per unit weight as the dependent variable in our analyses. This action
made the assumptions of normality and homoscedasticity (standard deviations were
equal) of our analyses reasonable’ [102].
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8b. Provide further relevant information on the provenance of animals, health/immune
status, genetic modification status, genotype, and any previous procedures.
Explanation. The animals’ provenance, their health or immune status, and their history of
previous testing or procedures can influence their physiology and behaviour, as well as their
response to treatments, and thus impact on study outcomes. For example, animals of the same
strain but from different sources, or animals obtained from the same source but at different
times, may be genetically different [16]. The immune or microbiological status of the animals
can also influence welfare, experimental variability, and scientific outcomes [112–114].
Report the health status of all animals used in the study and any previous procedures the
animals have undergone. For example, if animals are specific pathogen free (SPF), list the path-
ogens that they were declared free of. If health status is unknown or was not tested, explicitly
state this.
For genetically modified animals, describe the genetic modification status (e.g., knockout,
overexpression), genotype (e.g., homozygous, heterozygous), manipulated gene(s), genetic
methods and technologies used to generate the animals, how the genetic modification was
confirmed, and details of animals used as controls (e.g., littermate controls [115]).
Reporting the correct nomenclature is crucial to understanding the data and ensuring that
the research is discoverable and replicable [116–118]. Useful resources for reporting nomen-
clature for different species include
• Mice—International Committee on Standardized Genetic Nomenclature (https://www.
jax.org/jax-mice-and-services/customer-support/technical-support/genetics-and-
nomenclature)
• Rats—Rat Genome and Nomenclature Committee (https://rgd.mcw.edu/)
• Zebrafish—Zebrafish Information Network (http://zfin.org/)
• Xenopus—Xenbase (http://www.xenbase.org/entry/)
• Drosophila—FlyBase (http://flybase.org/)
• C. elegans—WormBase (https://wormbase.org/)
Examples
Subitem 8a—Example 1
‘One hundred and nineteen male mice were used: C57BL/6OlaHsd mice (n = 59), and
BALB/c OlaHsd mice (n = 60) (both from Harlan, Horst, The Netherlands). At the time
of the EPM test the mice were 13 weeks old and had body weights of 27.4 ± 0.4 g and
27.8 ± 0.3 g, respectively (mean ± SEM)’ [110].
Subitem 8a—Example 2
‘Histone Methylation Profiles and the Transcriptome of X. tropicalis Gastrula Embryos.
To generate epigenetic profiles, ChIP was performed using specific antibodies against
trimethylated H3K4 and H3K27 in Xenopus gastrula-stage embryos (Nieuwkoop-Faber
stage 11–12), followed by deep sequencing (ChIP-seq). In addition, polyA-selected RNA
(stages 10–13) was reverse transcribed and sequenced (RNA-seq)’ [111].
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Item 9. Experimental procedures
For each experimental group, including controls, describe the procedures in enough detail
to allow others to replicate them, including:
9a. What was done, how it was done, and what was used.
Explanation. Essential information to describe in the manuscript includes the procedures
used to develop the model (e.g., induction of the pathology), the procedures used to measure
the outcomes, and pre- and postexperimental procedures, including animal handling, welfare
monitoring, and euthanasia. Animal handling can be a source of stress, and the specific
method used (e.g., mice picked up by tail or in cupped hands) can affect research outcomes
[61,121,122]. Details about animal care and monitoring intrinsic to the procedure are
Examples
Subitem 8b—Example 1
‘A construct was engineered for knockin of the miR-128 (miR-128-3p) gene into the
Rosa26 locus. Rosa26 genomic DNA fragments (~1.1 kb and ~4.3 kb 50 and 30 homology
arms, respectively) were amplified from C57BL/6 BAC DNA, cloned into the pBasicL-
NeoL vector sequentially by in-fusion cloning, and confirmed by sequencing. The miR-
128 gene, under the control of tetO-minimum promoter, was also cloned into the vector
between the two homology arms. In addition, the targeting construct also contained a
loxP sites flanking the neomycin resistance gene cassette for positive selection and a
diphtheria toxin A (DTA) cassette for negative selection. The construct was linearized
with ClaI and electroporated into C57BL/6N ES cells. After G418 selection, seven-posi-
tive clones were identified from 121 G418-resistant clones by PCR screening. Six-posi-
tive clones were expanded and further analyzed by Southern blot analysis, among which
four clones were confirmed with correct targeting with single-copy integration. Cor-
rectly targeted ES cell clones were injected into blastocysts, and the blastocysts were
implanted into pseudo-pregnant mice to generate chimeras by Cyagen Biosciences Inc.
Chimeric males were bred with Cre deleted mice from Jackson Laboratories to generate
neomycin-free knockin mice. The correct insertion of the miR-128 cassette and success-
ful removal of the neomycin cassette were confirmed by PCR analysis with the primers
listed in Supplementary Table. . . ’ [119].
Subitem 8b—Example 2
‘The C57BL/6J (Jackson) mice were supplied by Charles River Laboratories. The C57BL/
6JOlaHsd (Harlan) mice were supplied by Harlan. The α-synuclein knockout mice were
kindly supplied by Prof. . .. (Cardiff University, Cardiff, United Kingdom.) and were
congenic C57BL/6JCrl (backcrossed for 12 generations). TNFα−/− mice were kindly
supplied by Dr. . .. (Queens University, Belfast, Northern Ireland) and were inbred on a
homozygous C57BL/6J strain originally sourced from Bantin & Kingman and generated
by targeting C57BL/6 ES cells. T286A mice were obtained from Prof. . .. (University of
California, Los Angeles, CA). These mice were originally congenic C57BL/6J (back-
crossed for five generations) and were then inbred (cousin matings) over 14 y, during
which time they were outbred with C57BL/6JOlaHsd mice on three separate occasions’
[120].
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discussed in further detail in Item 16. Animal care and monitoring. Provide enough detail to
enable others to replicate the methods and highlight any quality assurance and quality control
used [123,124]. A schematic of the experimental procedures with a timeline can give a clear
overview of how the study was conducted. Information relevant to distinct types of interven-
tions and resources are described in Table 1.
When available, cite the Research Resource Identifier (RRID) for reagents and tools used
[126,127]. RRIDs are unique and stable, allowing unambiguous identification of reagents or
tools used in a study, aiding other researchers to replicate the methods.
Detailed step-by-step procedures can also be saved and shared online, for example, using
Protocols.io [128], which assigns a digital object identifier (DOI) to the protocol and allows
cross-referencing between protocols and publications.
Table 1. Examples of information to include when reporting specific types of experimental procedures and
resources.
Procedures Resources
Pharmacological procedures (intervention and control)
• Drug formulation
• Dose
• Volume
• Concentration
• Site and route of administration
• Frequency of administration
• Vehicle or carrier solution formulation and volume
• Any evidence that the pharmacological agent used reaches the target tissue
Cell lines
• Identification
• Provenance
• Verification and
authentication
• RRID [126,127]
Surgical procedures (including sham surgery)
• Description of the surgical procedure
• Anaesthetic used (including dose and other information listed in
pharmacological procedures section above)
• Pre- and postanalgesia regimen
• Presurgery procedures (e.g., fasting)
• Aseptic techniques
• Monitoring (e.g., assessment of surgical anaesthetic plane)
• Whether the procedure is terminal or not
• Postsurgery procedures
• Duration of the procedure and duration of anaesthesia
• Physical variables measured
Reagents (e.g., antibodies,
chemicals)
• Manufacturer
• Supplier
• Catalogue number
• Lot number (if applicable)
• Purity of the drug (if
applicable)
• RRID
Pathogen infection (intervention and control)
• Infectious agent
• Dose load
• Vehicle or carrier solution formulation and volume
• Site and route of infection
• Timing or frequency of infection
Equipment and software
• Manufacturer
• Supplier
• Model/version number
• Calibration procedures (if
applicable)
• RRID
Euthanasia
• Method of euthanasia, including the humane standards the method complies
with, such as the AVMA [125]
• Pharmacological agent, if used (including dose and information listed in
pharmacological procedures section above)
• Any measures taken to reduce pain and distress before or during euthanasia
• Timing of euthanasia
• Tissues collected post-euthanasia and timing of collection
AVMA, American Veterinary Medical Association; RRID, Research Resource Identifier.
https://doi.org/10.1371/journal.pbio.3000411.t001
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Examples
Subitem 9a—Example 1
Subitem 9a—Example 2
‘For the diet-induced obesity (DIO) model, eight-week-old male mice had ad libitum
access to drinking water and were kept on standard chow (SFD, 10.9 kJ/g) or on western
high-fat diet (HFD; 22 kJ/g; kcal from 42% fat, 43% from carbohydrates and 15% from
protein; E15721-34, Ssniff, Soest, Germany) for 15 weeks (https://dx.doi.org/10.17504/
protocols.io.kbacsie)’ [130].
Subitem 9a—Example 3
‘The frozen kidney tissues were lysed. The protein concentration was determined with
the Pierce BCA assay kit (catalogue number 23225; Thermo Fisher Scientific, Rockford,
IL, USA). A total of 100–150 μg total proteins were resolved on a 6–12% SDS-PAGE gel.
Fig 4. This figure is an alternative version of the figure published in reference [129].
https://doi.org/10.1371/journal.pbio.3000411.g004
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9b. When and how often.
Explanation. Clearly report the frequency and timing of experimental procedures and mea-
surements, including the light and dark cycle (e.g., 12L:12D), circadian time cues (e.g., lights
on at 8:00 AM), and experimental time sequence (e.g., interval between baseline and compara-
tor measurements or interval between procedures and measurements). Along with innate cir-
cadian rhythms, these can affect research outcomes such as behavioural, physiological, and
immunological parameters [132,133]. Also report the timing and frequency of welfare assess-
ments, taking into consideration the normal activity patterns (see Item 16. Animal care and
monitoring). For example, nocturnal animals may not show behavioural signs of discomfort
during the day [134].
If the timing of procedures or measurements varies between animals, this information can
be provided as a supplementary table listing each animal.
9c. Where (including detail of any acclimatisation periods).
Explanation. Physiological acclimatisation after a stressful event, such as transport (e.g.,
between supplier, animal facility, operating theatre, and laboratory), but before the experiment
begins allows stabilisation of physiological responses of the animal [137,138]. Protocols vary
depending on species, strain, and outcome; for example, physiological acclimatisation follow-
ing transportation of different animals can take anywhere from 24 hours to more than 1 week
[139]. Procedural acclimatisation immediately before a procedure allows stabilisation of the
animals’ responses after unaccustomed handling, novel environments, and previous
Examples
Subitem 9b—Example 1
‘Blood pressure, heart rate, oxygen saturation and amount of blood extracted were
recorded every 5 minutes. Blood samples were drawn at baseline (pre injury), 0 minutes
(immediately after injury), and after 30 and 60 minutes’ [135].
Subitem 9b—Example 2
‘After a 5-h fast (7:30–12:30am), awake and freely moving mice were randomized and
subjected to three consecutive clamps performed in the same mice as described above,
with a 2 days recovery after each hyperinsulinemic/hypoglycemic (mHypo, n = 6) or
hyperinsulinemic/euglycemic (mEugly, n = 4) clamps’ [136].
The proteins were then transferred to a nitrocellulose membrane, blocked with 5%
skimmed milk for 1 h at room temperature and incubated overnight at 4˚C with primary
antibodies against the following proteins: proliferating cell nuclear antigen (PCNA; Cat#
2586, RRID: AB_2160343), phospho-AMPK (Cat# 2531, RRID: AB_330330), phospho-
mTOR (Cat# 2971, RRID: AB_330970). . .. The β-actin (Cat# A5441, RRID: AB_476744)
antibody was obtained from Sigma. The blots were subsequently probed with HRP-con-
jugated anti-mouse (Cat# A0216) or anti-rabbit IgG (Cat# A0208; Beyotime Biotechnol-
ogy, Beijing, China) at 1:1000. Immunoreactive bands were visualized by enhanced
chemiluminescence, and densitometry was performed using ImageJ software (RRID:
SCR_003070, Bio-Rad Laboratories)’ [131].
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procedures, which otherwise can induce behavioural and physiological changes [140,141].
Standard acclimatisation periods may vary between research laboratories, and this information
cannot be inferred by readers.
Indicate where studies were performed (e.g., dedicated laboratory space or animal facility,
home cage, open field arena, water maze) and whether periods of physiological or procedural
acclimatisation were included in the study protocol, including type and duration. If the study
involved multiple sites, explicitly state where each experiment and sample analysis was per-
formed. Include any accreditation of laboratories if appropriate (e.g., if samples were sent to a
commercial laboratory for analysis).
9d. Why (provide rationale for procedures).
Explanation. There may be numerous approaches to investigate any given research prob-
lem; therefore, it is important to explain why a particular procedure or technique was chosen.
This is especially relevant when procedures are novel or specific to a research laboratory or
constrained by the animal model or experimental equipment (e.g., route of administration
determined by animal size [143]).
Examples
Subitem 9d—Example 1
‘Because of the very small caliber of the murine tail veins, partial paravenous injection is
common if 18F-FDG is administered by tail vein injection (intravenous). This could
have significantly biased our comparison of the biodistribution of 18F-FDG under vari-
ous conditions. Therefore, we used intraperitoneal injection of 18F-FDG for our experi-
ments evaluating the influence of animal handling on 18F-FDG biodistribution’ [144].
Subitem 9d—Example 2
‘Since Xenopus oocytes have a higher potential for homologous recombination than fer-
tilized embryos. . . we next tested whether the host transfer method could be used for
efficient HDR-mediated knock-in. We targeted the C-terminus of X. laevis Ctnnb1 (β-
catenin), a key cytoskeletal protein and effector of the canonical Wnt pathway, because
previous studies have shown that addition of epitope tags to the C-terminus do not affect
the function of the resulting fusion protein (Fig . . .). CRISPR components were injected
into X. laevis oocytes followed by host transfer or into embryos’ [145].
Example
Subitem 9c –example 1
‘Fish were singly housed for 1 week before being habituated to the conditioning tank
over 2 consecutive days. The conditioning tank consisted of an opaque tank measuring
20 cm (w) 15 cm (h) 30 cm (l) containing 2.5L of aquarium water with distinct visual
cues (spots or stripes) on walls at each end of the tank. . .. During habituation, each indi-
vidual fish was placed in the conditioning apparatus for 20 minutes with free access to
both compartments and then returned to its home tank’ [142].
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Item 10. Results
For each experiment conducted, including independent replications, report:
10a. Summary/descriptive statistics for each experimental group, with a measure of var-
iability where applicable (e.g., mean and SD, or median and range).
Explanation. Summary/descriptive statistics provide a quick and simple description of the
data; they communicate quantitative results easily and facilitate visual presentation. For con-
tinuous data, these descriptors include a measure of central tendency (e.g., mean, median) and
a measure of variability (e.g., quartiles, range, standard deviation) to help readers assess the
precision of the data collected. Categorical data can be expressed as counts, frequencies, or
proportions.
Report data for all experiments conducted. If a complete experiment is repeated on a dif-
ferent day or under different conditions, report the results of all repeats rather than selecting
data from representative experiments. Report the exact number of experimental units per
group so readers can gauge the reliability of the results (see Item 2. Sample size and Item 3.
Inclusion and exclusion criteria). Present data clearly as text, in tables, or in graphs, to
enable information to be evaluated or extracted for future meta-analyses [146]. Report
descriptive statistics with a clearly identified measure of variability for each group. Fig 5
shows data summarised as means and standard deviations and, in brackets, ranges.
Box plots are a convenient way to summarise continuous data, plotted as median and inter-
quartile range, as shown in Fig 6.
Examples
Subitem 10a—Example 1
Fig 5. Reproduced from reference [147].
https://doi.org/10.1371/journal.pbio.3000411.g005
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10b. If applicable, the effect size with a confidence interval.
Explanation. In hypothesis-testing studies using inferential statistics, investigators fre-
quently confuse statistical significance and small p-values with biological or clinical impor-
tance [149]. Statistical significance is usually quantified and evaluated against a preassigned
threshold, with p< 0.05 often used as a convention. However, statistical significance is heavily
influenced by sample size and variation in the data (see Item 2. Sample size). Investigators
must consider the size of the effect that was observed and whether this is a biologically relevant
change.
Effect sizes are often not reported in animal research, but they are relevant to both explor-
atory and hypothesis-testing studies. An effect size is a quantitative measure that estimates the
magnitude of differences between groups or strength of relationships between variables. It can
be used to assess the patterns in the data collected and make inferences about the wider popu-
lation from which the sample came. The confidence interval for the effect indicates how pre-
cisely the effect has been estimated and tells the reader about the strength of the effect [150]. In
studies in which statistical power is low and/or hypothesis-testing is inappropriate, providing
the effect size and confidence interval indicates how small or large an effect might really be, so
a reader can judge the biological significance of the data [151,152]. Reporting effect sizes with
confidence intervals also facilitates extraction of useful data for systematic review and meta-
analysis. When multiple independent studies included in a meta-analysis show quantitatively
similar effects, even if each is statistically nonsignificant, this provides powerful evidence that a
relationship is ‘real’, although small.
Subitem 10a—Example 2
Fig 6. Reproduced from reference [148].
https://doi.org/10.1371/journal.pbio.3000411.g006
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Report all analyses performed, even those providing non-statistically significant results.
Report the effect size to indicate the size of the difference between groups in the study, with a
confidence interval to indicate the precision of the effect size estimate.
Recommended Set
The Recommended Set (Box 6) adds context to the study described, including further detail
about the methodology and advice on what to include in the more narrative parts of a manu-
script. Items are presented in a logical order; there is no ranking within the set.
Example
Subitem 10b—Example 1
Fig 7. Reproduced from reference [29].
https://doi.org/10.1371/journal.pbio.3000411.g007
Box 6. ARRIVE Recommended Set
11. Abstract
12. Background
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Item 11. Abstract
Provide an accurate summary of the research objectives, animal species, strain and sex, key
methods, principal findings, and study conclusions.
Explanation. A transparent and accurate abstract increases the utility and impact of the
manuscript and allows readers to assess the reliability of the study [153]. The abstract is often
used as a screening tool by readers to decide whether to read the full article or whether to select
an article for inclusion in a systematic review. However, abstracts often either do not contain
enough information for this purpose [11] or contain information that is inconsistent with the
results in the rest of the manuscript [154,155]. In systematic reviews, initial screens to identify
papers are based on titles, abstracts, and keywords [156]. Leaving out of the abstract informa-
tion such as the species of animal used or the drugs being tested limits the value of preclinical
systematic reviews as relevant studies cannot be identified and included. For example, in a sys-
tematic review of the effect of the MVA85A vaccine on tuberculosis challenge in animals, the
largest preclinical trial did not include the vaccine name in the abstract or keywords of the
publication; the paper was only included in the systematic review following discussions with
experts in the field [157].
To maximise utility, include details of the species, sex, and strain of animals used and accu-
rately report the methods, results, and conclusions of the study. Also describe the objectives of
the study, including whether it was designed either to test a specific hypothesis or to generate a
new hypothesis (see Item 13. Objectives). Incorporating this information will enable readers to
interpret the strength of evidence and judge how the study fits within the wider knowledge base.
Examples
Item 11—Example 1
‘Background and Purpose
‘Asthma is an inflammatory disease that involves airway hyperresponsiveness and
remodelling. Flavonoids have been associated to anti-inflammatory and antioxidant
activities and may represent a potential therapeutic treatment of asthma. Our aim was
to evaluate the effects of the sakuranetin treatment in several aspects of experimental
asthma model in mice.
13. Objectives
14. Ethical statement
15. Housing and husbandry
16. Animal care and monitoring
17. Interpretation/scientific implications
18. Generalisability/translation
19. Protocol registration
20. Data access
21. Declaration of interests
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‘Experimental Approach
‘Male BALB/c mice received ovalbumin (i.p.) on days 0 and 14, and were challenged
with aerolized ovalbumin 1% on days 24, 26 and 28. Ovalbumin-sensitized animals
received vehicle (saline and dimethyl sulfoxide, DMSO), sakuranetin (20 mg kg–1 per
mice) or dexamethasone (5 mg kg–1 per mice) daily beginning from 24th to 29th day.
Control group received saline inhalation and nasal drop vehicle. On day 29, we deter-
mined the airway hyperresponsiveness, inflammation and remodelling as well as specific
IgE antibody. RANTES, IL- 5, IL -4, Eotaxin, IL -10, TNF -α, IFN -γ and GMC-SF con-
tent in lung homogenate was performed by Bioplex assay, and 8-isoprostane and NF -kB
activations were visualized in inflammatory cells by immunohistochemistry.
‘Key Results
‘We have demonstrated that sakuranetin treatment attenuated airway hyperresponsive-
ness, inflammation and remodelling; and these effects could be attributed to Th2 pro-
inflammatory cytokines and oxidative stress reduction as well as control of NF -kB
activation.
‘Conclusions and Implications
‘These results highlighted the importance of counteracting oxidative stress by flavonoids
in this asthma model and suggest sakuranetin as a potential candidate for studies of
treatment of asthma’ [158].
Item 11—Example 2
‘In some parts of the world, the laboratory pig (Sus scrofa) is often housed in individual,
sterile housing which may impose stress. Our objectives were to determine the effects of
isolation and enrichment on pigs housed within the PigTurn1—a novel penning system
with automated blood sampling—and to investigate tear staining as a novel welfare indi-
cator. Twenty Yorkshire × Landrace weaner pigs were randomly assigned to one of four
treatments in a 2 × 2 factorial combination of enrichment (non-enriched [NE] or
enriched [E]) and isolation (visually isolated [I] or able to see another pig [NI]). Pigs
were catheterised and placed into the PigTurns1 48 h post recovery. Blood was collected
automatically twice daily to determine white blood cell (WBC) differential counts and
assayed for cortisol. Photographs of the eyes were taken daily and tear staining was quan-
tified using a 0–5 scoring scale and Image-J software to measure stain area and perime-
ter. Behaviour was video recorded and scan sampled to determine time budgets. Data
were analysed as an REML using the MIXED procedure of SAS. Enrichment tended to
increase proportion of time standing and lying laterally and decrease plasma cortisol,
tear-stain area and perimeter. There was a significant isolation by enrichment interac-
tion. Enrichment given to pigs housed in isolation had no effect on plasma cortisol, but
greatly reduced it in non-isolated pigs. Tear-staining area and perimeter were highest in
the NE-I treatment compared to the other three treatments. Eosinophil count was high-
est in the E-NI treatment and lowest in the NE-I treatment. The results suggest that in
the absence of enrichment, being able to see another animal but not interact may be frus-
trating. The combination of no enrichment and isolation maximally impacted tear stain-
ing and eosinophil numbers. However, appropriate enrichment coupled with proximity
of another pig would appear to improve welfare’ [159].
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Item 12. Background
12a. Include sufficient scientific background to understand the rationale and context for
the study, and explain the experimental approach.
Explanation. Scientific background information for an animal study should demonstrate a
clear evidence gap and explain why an in vivo approach was warranted. Systematic reviews of
the animal literature provide the most convincing evidence that a research question has not
been conclusively addressed, by showing the extent of current evidence within a field of
research. They can also inform the choice of animal model by providing a comprehensive
overview of the models used along with their benefits and limitations [160–162].
Describe the rationale and context of the study and how it relates to other research, includ-
ing relevant references to previous work. Outline evidence underpinning the hypothesis or
objectives and explain why the experimental approach is best suited to answer the research
question.
12b. Explain how the animal species and model used address the scientific objectives
and, where appropriate, the relevance to human biology.
Explanation. Provide enough detail for the reader to assess the suitability of the animal
model used to address the research question. Include information on the rationale for choos-
ing a particular species and explain how the outcome measures assessed are relevant to the
condition under study and how the model was validated. Stating that an animal model is com-
monly used in the field is not appropriate, and a well-considered, detailed rationale should be
provided.
When the study models an aspect of a human disease, indicate how the model is appropri-
ate for addressing the specific objectives of the study [164]. This can include a description of
Example
Subitem 12a –example 1
‘For decades, cardiovascular disease has remained the leading cause of mortality
worldwide. . . [and] cardiovascular research has been performed using healthy and
young, non-diseased animal models. Recent failures of cardioprotective therapies in
obese insulin-resistant . . ., diabetic . . ., metabolic syndrome-affected. . . and aged. . . ani-
mals that were otherwise successful in healthy animal models has highlighted the need
for the development of animal models of disease that are representative of human clini-
cal conditions. . .. The majority of laboratory-based studies investigating cardiovascular
disease and myocardial tolerance to ischemia-reperfusion (I-R) are currently conducted
using normogonadic models with either genetically-induced. . . or diet-induced. . . obe-
sity and metabolic syndrome (MetS). In the clinical setting, elderly male patients often
present with both testosterone deficiency (TD) and MetS. . .. A strong and compounding
association exists between metabolic syndrome and testosterone deficiency which may
have significant impact on cardiovascular disease and its outcomes which is not
addressed by current models. . .. Although laboratory investigations generally rely on
animal models of isolated metabolic syndrome or hypogonadism, their mutual presenta-
tion in the clinical setting warrants the development of appropriate animal models of the
MetS with hypogonadism, especially in the context of cardiovascular disease research’
[163].
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how the induction of the disease, disorder, or injury is sufficiently analogous to the human
condition; how the model responds to known clinically effective treatments; how similar
symptoms are to the clinical disease; and how animal characteristics were selected to represent
the age, sex, and health status of the clinical population [14].
Item 13. Objectives
Clearly describe the research question, research objectives and, where appropriate, specific
hypotheses being tested.
Explanation. Explaining the purpose of the study by describing the question(s) that the
research addresses allows readers to determine whether the study is relevant to them. Readers
can also assess the relevance of the model organism, procedures, outcomes measured, and
analysis used.
Knowing whether a study is exploratory or hypothesis-testing is critical to its interpretation.
A typical exploratory study may measure multiple outcomes and look for patterns in the data
or relationships that can be used to generate hypotheses. It may also be a pilot study, which
aims to inform the design or feasibility of larger subsequent experiments. Exploratory research
helps researchers to design hypothesis-testing experiments by choosing what variables or out-
come measures to focus on in subsequent studies.
Testing a specific hypothesis has implications for both the study design and the data analy-
sis [16,167]. For example, an experiment designed to detect a hypothesised effect will likely
need to be analysed with inferential statistics, and a statistical estimation of the sample size will
Examples
Subitem 12b—Example 1
‘For this purpose, we selected a pilocarpine model of epilepsy that is characterized by
robust, frequent spontaneous seizures acquired after a brain insult . . ., well-described
behavioral abnormalities . . ., and poor responses to antiepileptic drugs. . .. These ani-
mals recapitulate several key features of human temporal lobe epilepsy, the most com-
mon type of epilepsy in adults’ [165].
Subitem 12b—Example 2
‘Transplantation of healthy haematopoietic stem cells (HSCs) is a critical therapy for a
wide range of malignant haematological and non-malignant disorders and immune dys-
function. . .. Zebrafish are already established as a successful model to study the haema-
topoietic system, with significant homology with mammals. . .. Imaging of zebrafish
transparent embryos remains a powerful tool and has been critical to confirm that the
zebrafish Caudal Haematopoietic Tissue (CHT) is comparable to the mammalian foetal
haematopoietic niche. . .. Xenotransplantation in zebrafish embryos has revealed highly
conserved mechanisms between zebrafish and mammals. Recently, murine bone mar-
row cells were successfully transplanted into zebrafish embryos, revealing highly con-
served mechanism of haematopoiesis between zebrafish and mammals. . .. Additionally,
CD34 enriched human cells transplanted into zebrafish were shown to home to the
CHT and respond to zebrafish stromal-cell derived factors’ [166].
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need to be performed a priori (see Item 2. Sample size). Hypothesis-testing studies also have a
predefined primary outcome measure, which is used to assess the evidence in support of the
specific research question (see Item 6. Outcome measures).
In contrast, exploratory research investigates many possible effects and is likely to yield
more false positive results because some will be positive by chance. Thus, results from well-
designed hypothesis-testing studies provide stronger evidence than those from exploratory or
descriptive studies. Independent replication and meta-analysis can further increase the confi-
dence in conclusions.
Clearly outline the objective(s) of the study, including whether it is hypothesis-testing or
exploratory, or if it includes research of both types. Hypothesis-testing studies may collect
additional information for exploratory purposes; it is important to distinguish which hypothe-
ses were prespecified and which originated after data inspection, especially when reporting
unanticipated effects or outcomes that were not part of the original study design.
Item 14. Ethical statement
Provide the name of the ethical review committee or equivalent that has approved the use
of animals in this study and any relevant licence or protocol numbers (if applicable). If eth-
ical approval was not sought or granted, provide a justification.
Explanation. Authors are responsible for complying with regulations and guidelines relat-
ing to the use of animals for scientific purposes. This includes ensuring that they have the rele-
vant approval for their study from an appropriate ethics committee and/or regulatory body
Examples
Item 13—Example 1
‘The primary objective of this study was to investigate the cellular immune response
to MSC injected into the striatum of allogeneic recipients (6-hydroxydopamine
[6-OHDA]-hemilesioned rats, an animal model of Parkinson’s disease [PD]), and the
secondary objective was to determine the ability of these cells to prevent nigrostriatal
dopamine depletion and associated motor deficits in these animals’ [168].
Item 13—Example 2
‘In this exploratory study, we aimed to investigate whether calcium electroporation
could initiate an anticancer immune response similar to electrochemotherapy. To this
end, we treated immunocompetent balb/c mice with CT26 colon tumors with calcium
electroporation, electrochemotherapy, or ultrasound-based delivery of calcium or bleo-
mycin’ [169].
Item 13—Example 3
‘While characterizing a rab-6.2-null C. elegans strain for another study, we observed that
rab-6.2(ok2254) animals were fragile. We set out to analyze the fragile-skin phenotype in
rab-6.2(ok2254) animals genetically. . .. We observed several ruptured animals on our
rab-6.2(ok2254) culture plates during normal maintenance, a phenotype very rarely
observed in wild-type cultures. . .. We hypothesized that RAB-6.2 is required for skin
integrity’ [170].
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before the work starts. The ethical statement provides editors, reviewers, and readers with
assurance that studies have received this ethical oversight [12]. This also promotes transpar-
ency and understanding about the use of animals in research and fosters public trust.
Provide a clear statement explaining how the study conforms to appropriate regulations
and guidelines. Include the name of the institution where the research was approved and
the ethics committee who reviewed it (e.g., Institutional Animal Care and Use Committee
[IACUC] in the United States or Animal Welfare and Ethical Review Body [AWERB] in the
United Kingdom) and indicate protocol or project licence numbers so that the study can be
identified. Also add any relevant accreditation, e.g., American Association for Accreditation of
Laboratory Animal Care (AAALAC) [171] or Good Laboratory Practice (GLP).
If the research is not covered by any regulation and formal ethical approval is not required
(e.g., a study using animal species not protected by regulations or law), demonstrate that inter-
national standards were complied with and cite the appropriate reference. In such cases, pro-
vide a clear statement explaining why the research is exempt from regulatory approval.
Item 15. Housing and husbandry
Provide details of housing and husbandry conditions, including any environmental
enrichment.
Examples
Item 14—Example 1
‘All procedures were conducted in accordance with the United Kingdom Animal (Scien-
tific Procedures) Act 1986, approved by institutional ethical review committees (Alder-
ley Park Animal Welfare and Ethical Review Board and Babraham Institute Animal
Welfare and Ethical Review Board) and conducted under the authority of the Project
Licence (40/3729 and 70/8307, respectively)’ [172].
Item 14—Example 2
‘All protocols in this study were approved by the Committee on the Ethics of Animal
Experiments of Fuwai Hospital, Peking Union Medical College and the Beijing Council
on Animal Care, Beijing, China (IACUC permit number: FW2010-101523), in compli-
ance with the Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH publication no.85-23, revised 1996)’ [173].
Item 14—Example 3
‘Samples and data were collected according to Institut de Se´lection d’Animale (ISA) pro-
tocols, under the supervision of ISA employees. Samples and data were collected as part
of routine animal data collection in a commercial breeding program for layer chickens
in The Netherlands. Samples and data were collected on a breeding nucleus of ISA for
breeding purposes only, and is a non-experimental, agricultural practice, regulated by
the Act Animals, and the Royal Decree on Procedures. The Dutch Experiments on Ani-
mals Act does not apply to non-experimental, agricultural practices. An ethical review
by the Statement Animal Experiment Committee was therefore not required. No extra
animal discomfort was caused for sample collection for the purpose of this study’ [174].
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Explanation. The environment determines the health and wellbeing of the animals, and
every aspect of it can potentially affect their behavioural and physiological responses, thereby
affecting research outcomes [175]. Different studies may be sensitive to different environmen-
tal factors, and particular aspects of the environment necessary to report may depend on the
type of study [176]. Examples of housing and husbandry conditions known to affect animal
welfare and research outcomes are listed in Table 2; consider reporting these elements and any
other housing and husbandry conditions likely to influence the study outcomes.
Environment, either deprived or enriched, can affect a wide range of physiological and
behavioural responses [206]. Specific details to report include, but are not limited to, structural
enrichment (e.g., elevated surfaces, dividers); resources for species-typical activities (e.g., nest-
ing material, shelters, or gnawing sticks for rodents; plants or gravel for aquatic species); and
toys or other tools used to stimulate exploration, exercise (e.g., running wheel), and novelty.
If no environmental enrichment was provided, this should be clearly stated with justification.
Similarly, scientific justification needs to be reported for withholding food and water [207]
and for singly housing animals [208,209].
If space is an issue, relevant housing and husbandry details can be provided in the form of a
link to the information in a public repository or as supplementary information.
Table 2. Examples of information to consider when reporting housing and husbandry, and their effects on labora-
tory animals.
Information to report Examples of effects on laboratory animals
Cage/tank/housing system (type and
dimensions)
Affects behaviour [177] and fear learning [178]. Tank colour
affects stress in aquatic species [179,180].
Food and water (type, composition, supplier, and
access)
Affects body weight, tumour development, nephropathy severity
[181], and the threshold for developing parkinsonian symptoms
[182]. Maternal diet affects offspring body weight [183].
Bedding and nesting material Affects behavioural responses to stress [184] and pain [185].
Temperature and humidity Modifies tumour progression [186]. Regulates sexual
differentiation in zebrafish [187].
Sanitation (frequency of cage/tank water
changes, material transferred, water quality)
Affects blood pressure, heart rate, behaviour [188]. Adds an
additional source of variation [189,190].
Social environment (group size and
composition/stocking density)
Compromises animal welfare [191]. Induces aggressive
behaviour [192,193] and stress [180].
Biosecurity (level) The microbiological status of animals causes variation in
systemic disease parameters [194].
Lighting (type, schedule, and intensity) Modifies immune and stress responses [195].
Environmental enrichment Reduces anxiety [196,197], stress [196,197], and abnormal
repetitive behaviour [198–200]. Reduces susceptibility to
epilepsy [201] and osteoarthritis [202] and modifies the
pathology of neurological disorders [203]. Increases foraging
behaviour in fish [204].
Sex of the experimenter Affects physiological stress and pain behaviour [205].
https://doi.org/10.1371/journal.pbio.3000411.t002
Examples
Item 15—Example 1
‘Breeding colonies were kept in individually ventilated cages (IVCs; Tecniplast, Italy) at
a temperature of 20˚C to 24˚C, humidity of 50% to 60%, 60 air exchanges per hour in
the cages, and a 12/12-hour light/dark cycle with the lights on at 5:30 AM. The maxi-
mum caging density was five mice from the same litter and sex starting from weaning.
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Item 16. Animal care and monitoring
16a. Describe any interventions or steps taken in the experimental protocols to reduce
pain, suffering, and distress.
Explanation. A safe and effective analgesic plan is critical to relieve pain, suffering, and
distress. Untreated pain can affect the animals’ biology and add variability to the experiment;
however, specific pain management procedures can also introduce variability, affecting experi-
mental data [212,213]. Underreporting of welfare management procedures contributes to the
perpetuation of noncompliant methodologies and insufficient or inappropriate use of analge-
sia [213] or other welfare measures. A thorough description of the procedures used to alleviate
pain, suffering, and distress provides practical information for researchers to replicate the
method.
Clearly describe pain management strategies, including
• specific analgesic
• administration method (e.g., formulation, route, dose, concentration, volume, frequency,
timing, and equipment used)
• rationale for the choice (e.g., animal model, disease/pathology, procedure, mechanism of
action, pharmacokinetics, personnel safety)
• protocol modifications to reduce pain, suffering, and distress (e.g., changes to the anaesthetic
protocol, increased frequency of monitoring, procedural modifications, habituation, etc.)
If analgesics or other welfare measures, reasonably expected for the procedure performed,
are not performed for experimental reasons, report the scientific justification [214].
As bedding, spruce wood shavings (Lignocel FS-14; J. Rettenmaier und Soehne GmbH,
Rosenberg, Germany) were provided. Mice were fed a standardized mouse diet (1314,
Altromin, Germany) and provided drinking water ad libitum. All materials, including
IVCs, lids, feeders, bottles, bedding, and water were autoclaved before use. Sentinel
mice were negative for at least all Federation of laboratory animal science associations
(FELASA)-relevant murine infectious agents. . . as diagnosed by our health monitoring
laboratory, mfd Diagnostics GmbH, Wendelsheim, Germany’ [210].
Item 15—Example 2
‘Same sex litter mates were housed together in individually ventilated cages with two or
four mice per cage. All mice were maintained on a regular diurnal lighting cycle (12:12
light:-dark) with ad libitum access to food (7012 Harlan Teklad LM-485 Mouse/Rat Ster-
ilizable Diet) and water. Chopped corn cob was used as bedding. Environmental enrich-
ment included nesting material (Nestlets, Ancare, Bellmore, NY, USA), PVC pipe, and
shelter (Refuge XKA-2450-087, Ketchum Manufacturing Inc., Brockville, Ontario, Can-
ada). Mice were housed under broken barrier-specific pathogen-free conditions in the
Transgenic Mouse Core Facility of Cornell University, accredited by AAALAC (The
Association for Assessment and Accreditation of Laboratory Animal Care Interna-
tional)’ [211].
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16b. Report any expected or unexpected adverse events.
Explanation. Reporting adverse events allows other researchers to plan appropriate welfare
assessments and minimise the risk of these events occurring in their own studies. If the experi-
ment is testing the efficacy of a treatment, the occurrence of adverse events may alter the bal-
ance between treatment benefit and risk [34].
Report any adverse events that had a negative impact on the welfare of the animals in the
study (e.g., cardiovascular and respiratory depression, central nervous system disturbance,
hypothermia, reduction of food intake). Indicate whether they were expected or unexpected. If
adverse events were not observed, or not recorded during the study, explicitly state this.
Examples
Subitem 16b—Example 1
‘Murine lymph node tumors arose in 11 of 12 mice that received N2-transduced human
cells. The neo gene could be detected in murine cells as well as in human cells. Significant
lymphoproliferation could be seen only in the murine pre-T cells. It took 5 months for
murine leukemia to arise; the affected mice displayed symptoms of extreme sickness rap-
idly, with 5 of the 12 mice becoming moribund on exactly the same day (Figure . . .), and
6 others becoming moribund within a 1-month period. . .. Of the 12 mice that had
received N2-transduced human cells, 11 had to be killed because they developed visibly
enlarged lymph nodes and spleen, hunching, and decrease in body weight, as shown in
Figure. . .. The 12th mouse was observed carefully for 14 months; it did not show any
Examples
Subitem 16a—Example 1
‘If piglets developed diarrhea, they were placed on an electrolyte solution and provided
supplemental water, and if the diarrhea did not resolve within 48 h, piglets received a
single dose of ceftiofur (5.0 mg ceftiofur equivalent/kg of body weight i.m [Excede, Zoe-
tis, Florham Park, NJ]). If fluid loss continued after treatment, piglets then received a
single dose of sulfamethoxazole and trimethoprim oral suspension (50 mg/8 mg per mL,
Hi-Tech Pharmacal, Amityville, NY) for 3 consecutive days’ [215].
Subitem 16a—Example 2
‘One hour before surgery, we administered analgesia to the mice by offering them nut
paste (Nutella; Ferrero, Pino Torinese, Italy) containing 1 mg per kg body weight bupre-
norphine (Temgesic; Schering-Plough Europe, Brussels, Belgium) for voluntary inges-
tion, as described previously. . .. The mice had been habituated to pure nut paste for 2 d
prior to surgery’ [216].
Subitem 16a—Example 3
‘If a GCPS score equal or greater than 6 (out of 24) was assigned postoperatively, addi-
tional analgesia was provided with methadone 0.1 mg kg−1 IM (or IV if required) . . .
and pain reassessed 30 minutes later. The number of methadone doses was recorded’
[46].
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16c. Describe the humane endpoints established for the study, the signs that were moni-
tored, and the frequency of monitoring. If the study did not set humane endpoints, state this.
Explanation. Humane endpoints are predetermined morphological, physiological, and/or
behavioural signs that define the circumstances under which an animal will be removed from
an experimental study. The use of humane endpoints can help minimise harm while allowing
the scientific objectives to be achieved [219]. Report the humane endpoints that were estab-
lished for the specific study, species, and strain. Include clear criteria of the clinical signs moni-
tored [134] and clinical signs that led to euthanasia or other defined actions. Include details
such as general welfare indicators (e.g., weight loss, reduced food intake, abnormal posture)
and procedure-specific welfare indicators (e.g., tumour size in cancer studies [50], sensory-
motor deficits in stroke studies [220]).
Report the timing and frequency of monitoring, taking into consideration the normal circa-
dian rhythm of the animal and timing of scientific procedures, as well as any increase in the
frequency of monitoring (e.g., postsurgery recovery, critical times during disease studies, or
following the observation of an adverse event). Publishing score sheets of the clinical signs that
were monitored [221] can help guide other researchers to develop clinically relevant welfare
assessments, particularly for studies reporting novel procedures.
This information should be reported even if no animal reached any of the humane end-
points. If no humane endpoints were established for the study, explicitly state this.
Example
Subitem 16c—Example 1
‘Both the research team and the veterinary staff monitored animals twice daily. Health
was monitored by weight (twice weekly), food and water intake, and general assessment
of animal activity, panting, and fur condition. . .. The maximum size the tumors allowed
to grow in the mice before euthanasia was 2000 mm3’ [222].
signs of leukemia or other adverse events, and had no abnormal tissues when it was
autopsied. . .. The mice were observed at least once daily for signs of illness, which were
defined as any one or more of the following: weight loss, hunching, lethargy, rapid
breathing, skin discoloration or irregularities, bloating, hemi-paresis, visibly enlarged
lymph nodes, and visible solid tumors under the skin. Any signs of illness were logged as
“adverse events” in the experiment, the mouse was immediately killed, and an autopsy
was performed to establish the cause of illness’ [217].
Subitem 16b—Example 2
‘Although procedures were based on those reported in the literature, dogs under Proto-
col 1 displayed high levels of stress and many experienced vomiting. This led us to signif-
icantly alter procedures in order to optimize the protocol for the purposes of our own
fasting and postprandial metabolic studies’ [218].
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Item 17. Interpretation/scientific implications
17a. Interpret the results, taking into account the study objectives and hypotheses, current
theory, and other relevant studies in the literature.
Explanation. It is important to interpret the results of the study in the context of the study
objectives (see Item 13. Objectives). For hypothesis-testing studies, interpretations should be
restricted to the primary outcome (see Item 6. Outcome measures). Exploratory results derived
from additional outcomes should not be described as conclusive, as they may be underpow-
ered and less reliable.
Discuss the findings in the context of current theory, ideally with reference to a relevant sys-
tematic review, as individual studies do not provide a complete picture. If a systematic review
is not available, take care to avoid selectively citing studies that corroborate the results or only
those that report statistically significant findings [223].
When appropriate, describe any implications of the experimental methods or research find-
ings for improving welfare standards or reducing the number of animals used in future studies
(e.g., the use of a novel approach reduced the results’ variability, thus enabling the use of
smaller group sizes without losing statistical power). This may not be the primary focus of the
research, but reporting this information enables wider dissemination and uptake of refined
techniques within the scientific community.
17b. Comment on the study limitations, including potential sources of bias, limitations
of the animal model, and imprecision associated with the results.
Explanation. Discussing the limitations of the work is important to place the findings in
context, interpret the validity of the results, and ascribe a credibility level to its conclusions
[227]. Limitations are unavoidable in scientific research, and describing them is essential to
share experience, guide best practice, and aid the design of future experiments [228].
Example
Subitem 17a—Example 1
‘This is in contrast to data provided by an ‘intra-renal IL-18 overexpression’ model . . ., and
may reflect an IL-18 concentration exceeding the physiologic range in the latter study’ [224].
Subitem 17a—Example 2
‘The new apparatus shows potential for considerably reducing the number of animals
used in memory tasks designed to detect potential amnesic properties of new drugs. . .
approximately 43,000 animals have been used in these tasks in the past 5 years but with
the application of the continual trials apparatus we estimate that this could have been
reduced to 26,000 . . . with the new paradigm the number of animals needed to obtain
reliable results and maintain the statistical power of the tasks is greatly reduced’ [225].
Subitem 17a—Example 3
‘In summary, our results show that IL-1Ra protects against brain injury and reduces
neuroinflammation when administered peripherally to aged and comorbid animals at
reperfusion or 3 hours later. These findings address concerns raised in a recent system-
atic review on IL-1Ra in stroke. . . and provide further supporting evidence for IL-1Ra as
a lead candidate for the treatment of ischemic stroke’ [226].
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Discuss the quality of evidence presented in the study and consider how appropriate the
animal model is to the specific research question. A discussion on the rigour of the study
design to isolate cause and effect (also known as internal validity [229]) should include
whether potential risks of bias have been addressed [9] (see Item 2. Sample size, Item 3. Inclu-
sion and exclusion criteria, Item 4. Randomisation, and Item 5. Blinding).
Item 18. Generalisability/translation
Comment on whether, and how, the findings of this study are likely to generalise to other
species or experimental conditions, including any relevance to human biology (where
appropriate).
Explanation. An important purpose of publishing research findings is to inform future
research. In the context of animal studies, this might take the form of further in vivo research
or another research domain (e.g., human clinical trial). Thoughtful consideration is warranted,
as additional unnecessary animal studies are wasteful and unethical. Similarly, human clinical
trials initiated based on insufficient or misleading animal research evidence increase research
waste and negatively influence the risk-benefit balance for research participants [229,232].
Consider the type of study conducted to assess the implications of the findings. Well-
designed hypothesis-testing studies provide more robust evidence than exploratory studies
(see Item 13. Objectives). Findings from a novel, exploratory study may be used to inform
future research in a broadly similar context. Alternatively, enough evidence may have
Examples
Subitem 17b—Example 1
‘Although in this study we did not sample the source herds, the likelihood of these herds
to be IAV positive is high given the commonality of IAV infections in the Midwest. . ..
However, we cannot fully rule out the possibility that new gilts became infected with
resident viruses after arrival to the herd. Although new gilts were placed into isolated
designated areas and procedures were in place to minimize disease transmission (eg. iso-
lation, vaccination), these areas or procedures might not have been able to fully contain
infections within the designated areas’ [230].
Subitem 17b—Example 2
‘Even though our data demonstrates that sustained systemic TLR9 stimulation aggra-
vates diastolic HF in our model of gene-targeted diastolic HF, there are several limita-
tions as to mechanistic explanations of causality, as well as extrapolations to clinical
inflammatory disease states and other HF conditions. First, our pharmacological inflam-
matory model does not allow discrimination between effects caused by direct cardiac
TLR9 stimulation to that of indirect effects mediated by systemic inflammation. Second,
although several systemic inflammatory conditions have disturbances in the innate
immune system as important features, and some of these again specifically encompass-
ing distorted TLR9 signalling. . . sustained TLR9 stimulation does not necessarily repre-
sent a clinically relevant inflammatory condition. Finally, the cardiac myocyte SERCA2a
KO model does not adequately represent the molecular basis for, or the clinical features
of, diastolic HF’ [231].
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accumulated in the literature to justify further research in another species or in humans. Dis-
cuss what (if any) further research may be required to allow generalisation or translation. Dis-
cuss and interpret the results in relation to current evidence and, in particular, whether similar
[233] or otherwise supportive [234] findings have been reported by other groups. Discuss the
range of circumstances in which the effect is observed and factors that may moderate that
effect. Such factors could include, for example, the population (e.g., age, sex, strain, species),
the intervention (e.g., different drugs of the same class), and the outcome measured (e.g., dif-
ferent approaches to assessing memory).
Item 19. Protocol registration
Provide a statement indicating whether a protocol (including the research question, key
design features, and analysis plan) was prepared before the study, and if and where this
protocol was registered.
Explanation. Akin to the approach taken for clinical trials, protocol registration has
emerged as a mechanism that is likely to improve the transparency of animal research
[232,237,238]. Registering a protocol before the start of the experiment enables researchers to
demonstrate that the hypothesis, approach, and analysis were planned in advance and not
shaped by data as they emerged; it enhances scientific rigour and protects the researcher
against concerns about selective reporting of results [239,240]. A protocol should consist of (1)
the question being addressed and the key features of the research that is proposed, such as the
hypothesis being tested, the primary outcome measure (if applicable), and the statistical analy-
sis plan; and (2) the laboratory procedures to be used to perform the planned experiment.
Protocols may be registered with different levels of completeness. For example, in the Regis-
tered Report format offered by an increasing number of journals, protocols undergo peer
review, and if accepted, the journal commits to publishing the completed research regardless
of the results obtained [237].
Other online resources include the Open Science Framework [241], which is suitable to
deposit PHISPS (Population; Hypothesis; Intervention; Statistical Analysis Plan; Primary; Out-
come Measure; Sample Size Calculation) protocols [242] and provide researchers with the
Examples
Item 18—Example 1
‘Our results demonstrate that hDBS robustly modulates the mesolimbic network. This
finding may hold clinical relevance for hippocampal DBS therapy in epilepsy cases, as
connectivity in this network has previously been shown to be suppressed in mTLE. Fur-
ther research is necessary to investigate potential DBS-induced restoration of MTLE-
induced loss of functional connectivity in mesolimbic brain structures’ [235].
Item 18—Example 2
‘The tumor suppressor effects of GAS1 had been previously reported in cell cultures or
in xenograft models, this is the first work in which the suppressor activity of murine
Gas1 is reported for primary tumors in vivo. Recent advances in the design of safe vec-
tors for transgene delivery. . . may result in extrapolating our results to humans and so a
promising field of research emerges in the area of hepatic, neoplastic diseases’ [236].
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flexibility to embargo the preregistration, keep it from public view until the research is pub-
lished, and selectively share it with reviewers and editors. The EDA can also be used to gener-
ate a time-stamped PDF, which sets out key elements of the experimental design [19]. This can
be used to demonstrate that the study conduct, analysis, and reporting were not unduly driven
by emerging data. As a minimum, we recommend registering protocols containing all PHISPS
components as outlined above.
Provide a statement indicating whether or not any protocol was prepared before the study,
and if applicable, provide the time-stamped protocol or the location of its registration. When
there have been deviations from the protocol, describe the rationale for these changes in the
publication so that readers can take this into account when assessing the findings.
Item 20. Data access
Provide a statement describing if and where study data are available.
Explanation. A data-sharing statement describes how others can access the data on which
the paper is based. Sharing adequately annotated data allows others to replicate data analyses
so that results can be independently tested and verified. Data sharing allows the data to be
repurposed and new datasets to be created by combining data from multiple studies (e.g., to be
used in secondary analyses). This allows others to explore new topics and increases the impact
of the study, potentially preventing unnecessary use of animals and providing more value for
money. Access to raw data also facilitates text and automated data mining [246].
An increasing number of publishers and funding bodies require authors or grant holders to
make their data publicly available [247]. Journal articles with accompanying data may be cited
more frequently [248,249]. Datasets can also be independently cited in their own right, which
Examples
Item 19—Example 1
‘A detailed description of all protocols can be found in the Registered Report (Kandela
et al., 2015). Additional detailed experimental notes, data, and analysis are available on
the Open Science Framework (OSF) (RRID: SCR_003238) (https://osf.io/xu1g2/)’ [243].
Item 19—Example 2
‘To maximize the objectivity of the presented research, we preregistered this study
with its 2 hypotheses, its planned methods, and its complete plan of data analysis before
the start of data collection (https://osf.io/eb8ua/register/565fb3678c5e4a66b5582f67,
accessed 29 December 2017). We closely adhered to our plan. . .. All statistical analyses
closely followed our preregistered analysis plan (https://osf.io/eb8ua/)’ [244].
Item 19—Example 3
‘We preregistered our analyses with the Open Science Framework which facilitates
reproducibility and open collaboration in science research. . .. Our preregistration: Shel-
don and Griffith (2017), was carried out to limit the number of analyses conducted and
to validate our commitment to testing a limited number of a priori hypotheses. Our
methods are consistent with this preregistration . . .’ [245].
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provides additional credit for authors. This practice is gaining increasing recognition and
acceptance [250].
When possible, make available all data that contribute to summary estimates or claims pre-
sented in the paper. Data should follow the FAIR guiding principles [251]; that is, data are
findable, accessible (i.e., do not use outdated file types), interoperable (can be used on multi-
ple platforms and with multiple software packages), and reusable (i.e., have adequate data
descriptors).
Data can be made publicly available via a structured, specialised (domain-specific), open-
access repository such as those maintained by the National Center for Biotechnology Informa-
tion (NCBI, https://www.ncbi.nlm.nih.gov/) or European Bioinformatics Institute (EBI,
https://www.ebi.ac.uk/). If such a repository is not available, data can be deposited in unstruc-
tured but publicly available repositories (e.g., Figshare [https://figshare.com/], Dryad [https://
datadryad.org/], Zenodo [https://zenodo.org/], or Open Science Framework [https://osf.io/]).
There are also search platforms to identify relevant repositories with rigorous standards, e.g.,
FairSharing (https://fairsharing.org/) and re3data (https://www.re3data.org/).
Item 21. Declaration of interests
21a. Declare any potential conflicts of interest, including financial and nonfinancial. If
none exist, this should be stated.
Explanation. A competing or conflict of interest is anything that interferes with (or could
be perceived as interfering with) the full and objective presentation, analysis, and interpreta-
tion of the research. Competing or conflicts of interest can be financial or nonfinancial, profes-
sional or personal. They can exist in institutions, in teams, or with individuals. Potential
competing interests are considered in peer review, editorial, and publication decisions; the
aim is to ensure transparency, and in most cases, a declaration of a conflict of interest does not
obstruct the publication or review process.
Examples are provided in Box 7. If unsure, declare all potential conflicts, including both
perceived and real conflicts of interest [254].
Examples
Item 20—Example 1
‘Data Availability: All data are available from Figshare at http://dx.doi.org/10.6084/m9.
figshare.1288935’ [252].
Item 20—Example 2
‘A fundamental goal in generating this dataset is to facilitate access to spiny mouse tran-
script sequence information for external collaborators and researchers. The sequence
reads and metadata are available from the NCBI (PRJNA342864) and assembled tran-
scriptomes (Trinity_v2.3.2 and tr2aacds_v2) are available from the Zenodo repository
(https://doi.org/10.5281/zenodo.808870), however accessing and utilizing this data can be
challenging for researchers lacking bioinformatics expertise. To address this problem we
are hosting a SequenceServer. . . BLAST-search website (http://spinymouse.erc.monash.
edu/sequenceserver/). This resource provides a user-friendly interface to access sequence
information from the tr2aacds_v2 assembly (to explore annotated protein-coding tran-
scripts) and/or the Trinity_v2.3.2 assembly (to explore non-coding transcripts)’ [253].
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21b. List all funding sources (including grant identifier) and the role of the funder(s) in
the design, analysis, and reporting of the study.
Explanation. The identification of funding sources allows the reader to assess any com-
peting interests and any potential sources of bias. For example, bias, as indicated by a preva-
lence of more favourable outcomes, has been demonstrated for clinical research funded by
Box 7. Examples of competing or conflicts of interest
Financial
Funding and other payments received or expected by the authors directly arising from
the publication of the study, or funding or other payments from an organisation with an
interest in the outcome of the work.
Nonfinancial
Research that may benefit the individual or institution in terms of goods in kind. This
includes unpaid advisory position in a government, nongovernment organisation, or
commercial organisations.
Affiliations
Employed by, on the advisory board, or a member of an organisation with an interest in
the outcome of the work.
Intellectual property
Patents or trademarks owned by someone or their organisation. This also includes the
potential exploitation of the scientific advance being reported for the institution, the
authors, or the research funders.
Personal
Friends, family, relationships, and other close personal connections to people who may
potentially benefit financially or in other ways from the research.
Ideology
Beliefs or activism (e.g., political or religious) relevant to the work. Membership of a rele-
vant advocacy or lobbying organisation.
Examples
Subitem 21a—Example 1
‘The study was funded by Gubra ApS. LSD, PJP, GH, KF and HBH are employed by
Gubra ApS. JJ and NV are the owners of Gubra ApS. Gubra ApS provided support in
the form of materials and salaries for authors LSD, PJP, GH, KF, HBH, JJ and NV’ [255].
Subitem 21a—Example 2
‘The authors have declared that no competing interests exist’ [256].
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industry compared with studies funded by other sources [257–259]. Evidence for preclinical
research also indicates that funding sources may influence the interpretation of study out-
comes [254,260].
Report the funding information including the financial supporting body(s) and any grant
identifier(s). If the study was supported by several sources of funding, list them all, including
internal grants. Specify the role of the funder in the design, analysis, reporting, and/or decision
to publish. If the research did not receive specific funding but was performed as part of the
employment of the authors, name the employer.
Supporting information
S1 Annotated Byline. Individual authors’ positions at the time this article was submitted.
(DOCX)
S1 Annotated References. Further context on the works cited in this article.
(DOCX)
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Examples
Subitem 21b—Example 1
‘Support was provided by the Italian Ministry of Health: Current research funds PRC
2010/001 [http://www.salute.gov.it/] to MG. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript’ [261].
Subitem 21b—Example 2
‘This study was financially supported by the Tuberculosis and Lung Research Center of
Tabriz University of Medical Sciences and the Research Council of University of Tabriz.
The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript’ [262].
Subitem 21b—Example 3
‘This work was supported by the salary paid to AEW. The funder had no role in study
design, data collection and analysis, decision to publish, or preparation of the manu-
script’ [263].
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